<SEC-DOCUMENT>0001104659-24-109532.txt : 20241017
<SEC-HEADER>0001104659-24-109532.hdr.sgml : 20241017
<ACCEPTANCE-DATETIME>20241017161013
ACCESSION NUMBER:		0001104659-24-109532
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20241017
DATE AS OF CHANGE:		20241017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mind Medicine (MindMed) Inc.
		CENTRAL INDEX KEY:			0001813814
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280548
		FILM NUMBER:		241377706

	BUSINESS ADDRESS:	
		STREET 1:		ONE WORLD TRADE CENTER
		STREET 2:		SUITE 8500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
		BUSINESS PHONE:		212-220-6633

	MAIL ADDRESS:	
		STREET 1:		ONE WORLD TRADE CENTER
		STREET 2:		SUITE 8500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>tm2423581-3_424b7.htm
<DESCRIPTION>424B7
<TEXT>
<html>
  <head>
    <title>tm2423581-3_424b7 - none - 5.1170682s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed Pursuant to Rule&#160;424(b)(7)</font>&#8203;</div>
        <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-280548</font>&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT </font> <br ><font style="letter-spacing:-0.2pt;">(To Prospectus Dated June&#160;28, 2024)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to 8,000,000 Common Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_mindmed-4c.jpg" alt="[MISSING IMAGE: lg_mindmed-4c.jpg]" height="48" width="216" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Offered by the Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:11.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus supplement under the caption &#8220;Selling Stockholders,&#8221; of up to 8,000,000 of our common shares, without par value (the &#8220;common shares&#8221;), issuable upon the exercise of the Exchange Warrants (as defined herein) issued to the selling stockholders pursuant to the Exchange Agreement (as defined herein). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will not receive any proceeds from the sale of the common shares offered by this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may offer and sell or otherwise dispose of the common shares described in this prospectus supplement from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholders will bear all selling commissions applicable to the sales of common shares and all fees and expenses of legal counsel for the selling stockholders, subject to certain specified exceptions. We will bear all other costs, expenses and fees in connection with the registration of the common shares. See the section entitled &#8220;Plan of Distribution&#8221; for more information about how the selling stockholders may sell or dispose of their common shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may amend or supplement this prospectus supplement from time to time by filing supplements as required. You should carefully read this prospectus supplement and any supplements to this prospectus supplement, together with any documents incorporated by reference herein or therein, before you make your investment decision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may sell any, all or none of the common shares offered by this prospectus supplement and we do not know when or in what amount the selling stockholders may sell their common shares hereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common shares are listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;MNMD&#8221;. The last reported sale price of our common shares on October 16, 2024 was $6.49 on Nasdaq. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings. See &#8220;Implications of Being an Emerging Growth Company.&#8221; </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common shares involves a high degree of risk. See &#8220;Risk Factors&#8221; on page <a href="#sRIFA">S-8</a> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state or other securities commission has approved or disapproved of the common shares or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:65pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus supplement is October 17, 2024.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a><a name="GoBack">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:91.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">P</font><font style="text-transform:lowercase;letter-spacing:-0.2pt;">ROSPECTUS</font><font style="letter-spacing:-0.2pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.2pt;">UPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:188.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:425.15pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sATPS"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sATPS">S-ii</a></font> <a href="#sATPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPRSU">S-1</a></font> <a href="#sPRSU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sTHOF">S-7</a></font> <a href="#sTHOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sRIFA">S-8</a></font> <a href="#sRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSNRF">S-9</a></font> <a href="#sSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sUOP">S-11</a></font> <a href="#sUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSEST"><font style="letter-spacing:0.2pt;">SELLING STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSEST">S-12</a></font> <a href="#sSEST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPOD">S-14</a></font> <a href="#sPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLEMA">S-16</a></font> <a href="#sLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sEXP">S-16</a></font> <a href="#sEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sWYCF">S-16</a></font> <a href="#sWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sIBR">S-17</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">P</font><font style="text-transform:lowercase;letter-spacing:-0.2pt;">ROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:250pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">1</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIAO"><font style="letter-spacing:0.2pt;">MARKET, INDUSTRY AND OTHER DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMIAO">3</a></font> <a href="#tMIAO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">THE COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">4</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">8</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">9</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSESE"><font style="letter-spacing:0.2pt;">SELLING SECURITYHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSESE">10</a></font> <a href="#tSESE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">11</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tGDOO"><font style="letter-spacing:0.2pt;">GENERAL DESCRIPTION OF OUR SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tGDOO">14</a></font> <a href="#tGDOO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOC"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR COMMON SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOC">15</a></font> <a href="#tDOOC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOW">16</a></font> <a href="#tDOOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOD"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOD">18</a></font> <a href="#tDOOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOU"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR UNITS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOU">23</a></font> <a href="#tDOOU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">24</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">24</a></font> <a href="#tIBR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">24</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">25</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 (File No. 333-280548) that went effective upon filing with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) on June&#160;28, 2024 using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling stockholders may, from time to time, sell the common shares offered by them in this prospectus supplement in one or more offerings through any means described in the section entitled &#8220;Plan of Distribution.&#8221; We will not receive any proceeds from the sale by the selling stockholders of the common shares offered by them in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement provides you with a general description of the common shares that may be offered. To the extent necessary, each time that the selling stockholders offer and sell common shares, we or the selling stockholders may supplement this prospectus supplement to provide specific information about the common shares being offered and sold and the specific terms of that offering. To the extent permitted by law, we may also authorize one or more free writing prospectuses that may contain material information relating to these offerings. Such prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus supplement with respect to that offering. If there is any inconsistency between the information in this prospectus supplement and the subsequently filed prospectus supplement or free writing prospectus, you should rely on the subsequently filed prospectus supplement or free writing prospectus, as applicable. Before purchasing any of our common shares, you should carefully read both this prospectus supplement and any subsequently filed prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the selling stockholders have authorized anyone to provide you with any information or to make any representations other than those contained, or incorporated by reference, in this prospectus supplement, any subsequently filed prospectus supplement or in any related free writing prospectus. Neither we nor the selling stockholders take any responsibility for, nor provide any assurance as to the reliability of, any other information that others may give you. This prospectus supplement and any subsequently filed prospectus supplement or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any common shares other than the common shares described in the applicable prospectus supplement or an offer to sell or the solicitation of an offer to buy such common shares in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement and any subsequently filed prospectus supplement is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference herein or therein is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, any subsequently filed prospectus supplement or free writing prospectus, and the documents incorporated by reference herein or therein contain summaries of certain provisions contained in some of the documents described or incorporated by reference herein and therein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the section entitled &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For investors outside of the United States: neither we nor the selling stockholders have done anything that would permit this offering or possession or distribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of our common shares and the distribution of this prospectus supplement outside the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise indicated or unless the context otherwise requires, references to &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to Mind Medicine (MindMed) Inc. and its consolidated subsidiaries and references to dollars or dollar amounts refer to U.S. dollars or U.S. dollar amounts. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:544pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement may contain references to our trademarks and trade names and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus supplement may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> or &#8482; symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us or our business by, any other companies.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus supplement, the accompanying prospectus or incorporated by reference herein and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus supplement, the accompanying prospectus and any related free writing prospectus, including the risks of investing in our common shares discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus supplement, the accompanying prospectus and any applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus supplement is a part, before making your investment decision.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including MM120 and MM402, our lead product candidates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of generalized anxiety disorder (&#8220;GAD&#8221;). We have also evaluated MM120 in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;). In December&#160;2023, we announced positive topline results from our Phase&#160;2b clinical trial of MM120 for the treatment of GAD. The trial met its primary endpoint, with MM120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety Rating Scale (&#8220;HAM-A&#8221;) compared to placebo at Week 4. In January&#160;2024, we announced that our Phase&#160;2a trial of a sub-perceptual dose of MM120 in ADHD did not meet its primary endpoint. In conjunction with the findings from our clinical trial of MM120 in GAD, we believe that these results support the critical role of perceptual effects of MM120 in mediating a clinical response. In March&#160;2024, we announced that the FDA granted breakthrough designation to our MM120 program for the treatment of GAD. We also announced in March&#160;2024 that our Phase&#160;2b trial of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On June&#160;20, 2024, we announced the completion of our End-of-Phase&#160;2 meeting with the FDA, supporting the advancement of MM120 into pivotal trials for the treatment of adults with GAD. Our Phase&#160;3 clinical program for MM120 ODT is expected to consist of two clinical trials: the Voyage Study (MM120-300) and the Panorama Study (MM120-301). Both studies are comprised of two parts: Part&#160;A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part&#160;B, which is a 40-week extension study during which participants will be eligible for open-label treatment with MM120, subject to certain conditions for re-treatment eligibility. The Voyage Study is anticipated to enroll approximately 200 participants (randomized&#160;1:1 to receive MM120 ODT 100 &#181;g or placebo) and the Panorama Study is anticipated to enroll approximately 240 participants (randomized 5:2:5 to receive MM120 ODT 100 &#181;g, MM120 ODT 50 &#181;g or placebo). We expect both studies will utilize an adaptive study design with a blinded interim sample size re-estimation, allowing for an increase in sample size by up to 50% in each study in the case of certain parameters. We expect the primary endpoint for each study is the change from baseline in HAM-A score at Week 12 between MM120 ODT 100 &#181;g and placebo. We expect to initiate the Voyage Study in the second half of 2024 with an anticipated topline readout (Part&#160;A results) in the first half of 2026, and we expect to initiate the Panorama Study in the first half of 2025 with an anticipated topline readout (Part&#160;A results) in the second half of 2026. Both studies are subject to ongoing regulatory review and discussions, which could result in changes to study design, including of the Phase&#160;3 clinical trials. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to our Phase&#160;3 clinical program for GAD, we are developing MM120 for the treatment of Major Depressive Disorder (&#8220;MDD&#8221;). In the first quarter of 2024, we held a pre-IND meeting with FDA to discuss the initiation of our MM120 MDD program and the study design for our planned Emerge Study (MM120-310), which like our pivotal studies in GAD is comprised of two parts: Part&#160;A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part&#160;B, which is a 40-week extension study during which participants will be eligible for open-label treatment with MM120, subject to certain conditions for re-treatment eligibility. The Emerge Study is anticipated to enroll at least 140 participants (randomized 1:1 to receive MM120 ODT 100 &#181;g or placebo). The primary endpoint is the change from baseline in Montgomery &#197;sberg Depression Rating Scale (MADRS) score at Week 6 between MM120 ODT 100 &#181;g and placebo. We expect to initiate the Emerge Study in the first half of 2025 with an anticipated topline readout (Part&#160;A results) in the second half of 2026. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to the findings from our Phase&#160;2b trial on comorbid depressive symptoms in GAD patients, additional evidence for the potential of lysergide in the treatment of MDD is available from a double-blind, investigator-initiated trial of lysergide in participants with MDD conducted by our collaborators at University Hospital Basel (&#8220;UHB&#8221;). In this trial, 61 participants were randomized to receive one of two treatment regimens of lysergide. Each regimen consisted of two treatment sessions separated by four weeks. In the high-dose regimen, participants received 100 &#181;g in their first dosing session and either 100 &#181;g or 200 &#181;g in their second dosing session. In the control regimen, participants received 25 &#181;g in each dosing session. The high-dose regimen (n=28) demonstrated statistically and clinically significant improvements on the primary endpoint, which was the change in clinician-rated Inventory of Depressive Symptomatology&#8201;&#8212;&#8201;Clinical Rating (&#8220;IDS-C&#8221;) scores six weeks after the first treatment session compared to the control regimen (n=27). Participants in the high-dose regimen demonstrated a least square mean change from baseline in IDS-C scores of <font style="white-space:nowrap;">-12.9</font> points compared to <font style="white-space:nowrap;">-3.6</font> points in the control regimen (p=0.05). The statistically significant benefit measured by IDS-C was maintained up to 16 weeks after the first session of the high-dose regimen compared to the control-dose regimen (p=0.01). According to the results reported by UHB, lysergide was generally well-tolerated in the trial, as indicated by adverse events, vital signs and laboratory values. UHB reported four serious adverse events (&#8220;SAEs&#8221;) during the trial, three of which were determined to be &#8220;possibly related&#8221; to the treatment. These SAEs were two hospitalizations due to worsening depression in the control regimen and one in the high-dose regimen. UHB noted that a participant in the control regimen who withdrew from the trial after such participant&#8217;s first session died of suicide seven&#160;months later. No treatment association was suspected and this was not reported as an SAE because it occurred after the participant withdrew from the trial. Secondary outcome measures for the trial included improvements in the self-rated version of the Inventory of Depressive Symptomatology&#8201;&#8212;&#8201;Self Report (IDS-SR), Beck Depression Inventory (BDI), and State-Trait Anxiety Inventory (STAI-G), along with other psychiatric symptom assessments. Participants were followed for up to 16 weeks following the first treatment session. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our second lead product candidate, MM402, also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (&#8220;MDMA&#8221;), which we are developing for the treatment of autism spectrum disorder. MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrated its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggests that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. In the third quarter of 2022, UHB began conducting a Phase&#160;1 investigator-initiated trial (&#8220;IIT&#8221;) of R(-)-MDMA, S(+)-MDMA and R/S-MDMA in healthy volunteers to compare the tolerability, pharmacokinetics and acute subjective, physiological and endocrine effects of the three molecules. On June&#160;6, 2024, UHB presented topline data from the trial at the Interdisciplinary Conference on Psychedelic Research in The Netherlands. The presentation noted that the trial indicates that R(-)-MDMA, S(+)-MDMA and R/S-MDMA induced overall similar qualitative subjective and adverse effects when dosed equivalently. The presentation also noted that S(+)-MDMA may have slightly greater stimulant like properties than R/S-MDMA and R(-)-MDMA. The pharmacokinetic findings from the trial indicate that R(-)-MDMA, but not S(+)-MDMA, inhibits the Cytochrome P450 2D6 enzyme (CYP2D6), which is the primary metabolic pathway for MDMA inactivation, and thereby its own inactivation and that of S(+)-MDMA when administered as R/S-MDMA. In addition, we have initiated our first clinical trial of MM402, a single-ascending dose trial in adult </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">healthy volunteers in the fourth quarter of 2023. This Phase&#160;1 clinical trial is intended to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM402. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Beyond our clinical stage product candidates, we are pursuing a number of programs, primarily through external collaborations, through which we seek to expand our drug development pipeline and broaden the potential applications of our lead product candidates. These research and development programs include non-clinical, pre-clinical and human clinical trials and IITs of additional product candidates and research compounds with our collaborators. Our external research programs include a broad multi-year exclusive research partnership with UHB in Switzerland. We also have an ongoing partnership agreement with MindShift Compounds AG to develop next-generation compounds utilizing the molecular backbone of classical psychedelics and empathogens. Our research partnerships and IITs facilitate the advancement of our early-stage pipeline and support the potential identification of product candidates for additional company-sponsored drug development programs. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our drug development program is complemented by digital medicine projects to develop products intended to help facilitate the adoption and scalability of our product candidates, if and when they are approved. Our digital medicine projects and product roadmaps strategies, and investments are based on the projected development and commercialization strategies of our product candidates, with timelines and investments for each project contingent on the progression of the related drug program. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our business is premised on a growing body of research supporting the use of novel psychoactive compounds to treat a myriad of brain health disorders. For all product candidates, we intend to proceed through research and development, and with marketing of the product candidates that may ultimately be approved pursuant to the regulations of the FDA and the legislation in other jurisdictions. This entails, among other things, conducting clinical trials with research scientists, using internal and external clinical drug development teams, producing and supplying drugs according to current Good Manufacturing Practices, and conducting all trials and development in accordance with the regulations of the FDA, and other legislation in other jurisdictions. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Product Candidate Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following table summarizes the status of our portfolio of product candidates: </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="tb_candidate-4clr.jpg" alt="[MISSING IMAGE: tb_candidate-4clr.jpg]" height="241" width="608" >
          </div>
          <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Description of the Transaction</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are registering the offer and resale of an aggregate of up to 8,000,000 common shares hereunder, issuable upon the exercise of the Exchange Warrants issued to the selling stockholders in accordance with the Exchange Agreement, on behalf of the selling stockholders, to be offered and sold by the selling stockholders from time to time. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Private Placement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On March&#160;7, 2024, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with the selling stockholders, pursuant to which we issued an aggregate of 12,500,000 common shares to the selling stockholders (the &#8220;Private Placement Shares&#8221;) at a price of $6.00 per share in a private placement transaction (the &#8220;Private Placement&#8221;). </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In connection with the Private Placement, we also entered into a registration rights agreement, dated March&#160;7, 2024 (the &#8220;Registration Rights Agreement&#8221;), with the selling stockholders requiring us to register the resale of the Private Placement Shares, which were subsequently registered pursuant to a registration statement on Form S-3 that was declared effective on April&#160;29, 2024 by the SEC. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Exchange</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">On October 17, 2024, we entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with the selling stockholders pursuant to which we exchanged an aggregate of 8,000,000 common shares purchased by the selling stockholders in the Private Placement for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 8,000,000 common shares with an exercise price of $0.001 per share (the &#8220;Exchange Shares&#8221;). The Exchange Warrants were issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), afforded by Section&#160;3(a)(9) of the Securities Act. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Exchange Warrants are exercisable at any time after the date of issuance. The exercise price and the number of Exchange Shares are subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications or similar events affecting our common shares as well as upon any distribution of assets, including cash, securities or other property, to our shareholders. The Exchange Warrants will not expire and are exercisable in cash or by means of a cashless exercise. The selling stockholders may not exercise the Exchange Warrants if the aggregate number of common shares beneficially owned by the selling stockholders, together with its affiliates, would exceed more than 9.99% of the number of common shares outstanding following such exercise, as such&#160;percentage ownership is determined in accordance with the terms of the Exchange Warrants. The selling stockholders may increase or decrease this&#160;percentage not in excess of 19.99% by providing at least 61&#160;days&#8217; prior notice to us. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In connection with entering into the Exchange Agreement, we also entered into an amendment to the Registration Rights Agreement, pursuant to which we have agreed to register the resale of the Exchange Shares. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Associated with our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">There are a number of risks related to our business, this offering and our common shares that you should consider before you decide to invest in our common shares. You should carefully consider all the information presented in the section entitled &#8220;Risk Factors&#8221; in this prospectus supplement and in the section entitled &#8220;Risk Factors&#8221; in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a>, which is incorporated by reference in this prospectus supplement, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus supplement. Some of the principal risks related to our business include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have a limited operating history, have not initiated or completed any large-scale or pivotal clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are a clinical-stage pharmaceutical company and have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have never generated revenue and may never be profitable. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are dependent on the successful development of our product candidates. We cannot give any assurance that any of our product candidates will successfully complete clinical trials or receive regulatory approval, which is necessary before a product candidate can be commercialized. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, which would mean that we would be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our focus is on product candidates that are subject to controlled substance laws and regulations in the territories where the products are being developed and will be marketed, if approved, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations and our financial condition, both during clinical development and post approval, if any. In addition, the FDA and/or other regulatory bodies may require additional data, including with respect to abuse potential of our product candidates, before allowing us to commence a clinical trial or before approving any future marketing application we may submit. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our product candidates are controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding controlled substances and psychedelics may negatively influence the success of our product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We may not achieve our publicly announced milestones according to schedule, or at all. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those product candidates and decrease our ability to generate revenue. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We face competition from other biotechnology and pharmaceutical companies and our financial condition and operations will suffer if we fail to effectively compete. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, academic collaborators and contract research organizations, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our business and operations could be negatively affected if we become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategies and impact our share price. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act enacted in April&#160;2012, and we will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the first fiscal year in which we have more than $1.235&#160;billion in annual revenue; (2)&#160;the date on which we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by non-affiliates; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;following the fifth anniversary of the date of the first sale of our common equity securities under an effective registration statement under the Securities Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the Province of British Columbia. Our wholly owned subsidiary, Mind Medicine, Inc. (&#8220;MindMed US&#8221;), was incorporated in Delaware. Prior to February&#160;27, 2020, our operations were conducted through MindMed US. Our office is located at One World Trade Center, Suite&#160;8500, New York, New York 10007, and our telephone number at that location is (212) 220-6633. Our website address is https://mindmed.co. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into this prospectus supplement. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:173pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Common shares registered for sale by selling stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:197pt; margin-top:-12pt; width:259pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 8,000,000 common shares. </font>
          </div>
          <div style="width:173pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Use of proceeds</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:197pt; margin-top:-12pt; width:259pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will not receive any proceeds from the sale of the common shares by the selling stockholders. See &#8220;Use of Proceeds&#8221; for additional information. </font>
          </div>
          <div style="width:173pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Offering price</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:197pt; margin-top:-12pt; width:259pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The selling stockholders may sell all or a portion of their common shares through public or private transactions at prevailing market prices or at privately negotiated prices. See &#8220;Plan of Distribution&#8221; for additional information. </font>
          </div>
          <div style="width:173pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Risk factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:197pt; margin-top:-12pt; width:259pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the &#8220;Risk Factors&#8221; section in this prospectus supplement and in the section entitled &#8220;Risk Factors&#8221; in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a>, which is incorporated by reference in this prospectus supplement, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus supplement for a discussion of factors to consider carefully before deciding to invest in our common shares. </font>
          </div>
          <div style="width:173pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Nasdaq Global Select Market symbol</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:197pt; margin-top:-12pt; width:259pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our common shares are listed on Nasdaq under the symbol &#8220;MNMD&#8221;.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:normal;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:normal;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our common shares involves a high degree of risk. Before making an investment decision regarding our common shares, you should consider carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a>, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus supplement and the risk factors and other information contained in any subsequently filed prospectus supplement and any applicable free writing prospectus. These risks and uncertainties could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our common shares, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also carefully read the sections entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Incorporation by Reference.&#8221;</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:normal;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:normal;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, the documents that we incorporate by reference herein, contain, and any free writing prospectus that we authorize for use may contain, forward-looking statements within the meaning of Section&#160;27A of the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus supplement, the accompanying prospectus, the documents that we incorporate by reference herein, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward- looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, progress and results of our investigational programs for MM120, a proprietary, pharmaceutically optimized form of lysergide D-tartrate, MM402, also referred to as R(-)-MDMA (together, our &#8220;lead product candidates&#8221;) and any other product candidates (together with our lead product candidates, our &#8220;product candidates&#8221;), including statements regarding the timing of initiation and completion of trials or studies and related preparatory work, the period during which the results of the trials will become available and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance on the success of our investigational MM120 product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the protocols and timing of the initiation and availability of data from our proposed Phase&#160;3 clinical program for MM120 orally disintegrating tablet in GAD; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the protocol and timing of the initiation and availability of data from our proposed Phase&#160;3 clinical program for MM120 in MDD; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, scope or likelihood of regulatory filings and approvals and our ability to obtain and maintain regulatory approvals for product candidates for any indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the size of the eligible patient populations for our lead product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify third-party treatment sites to conduct our trials and our ability to identify and train appropriate qualified healthcare practitioners to administer our treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to implement our business model and our strategic plans for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify new indications for our lead product candidates beyond our current primary focuses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify, develop or acquire digital technologies to enhance our administration of our product candidates, if they should become approved and commercialized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to achieve profitability and then sustain such profitability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercialization, marketing and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the pricing, coverage and reimbursement of our lead product candidates, if approved and commercialized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance and clinical utility of our lead product candidates, in particular, and controlled substances, in general; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">future investments in our business, our anticipated capital expenditures and our estimates regarding our capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish or maintain collaborations or strategic relationships or to obtain additional funding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding potential benefits of our lead product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain effective patent rights and other intellectual property protection for our product candidates, and to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">infringement or alleged infringement on the intellectual property rights of third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">legislative and regulatory developments in the United States, including individual states, Canada, the United Kingdom, and other jurisdictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effectiveness of our internal control over financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">actions of activist shareholders against us have been and could be disruptive and costly and may result in litigation and have an adverse effect on our business and share price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of adverse global economic conditions, including public health crises, geopolitical conflicts, fluctuations in interest rates, supply-chain disruptions and inflation, on our financial condition and operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Loan and Security Agreement with K2 HealthVentures LLC, as administrative agent and Canadian collateral agent for the lenders thereunder, and Ankura Trust Company, LLC, as collateral trustee, contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding our future revenue, expenses and other operating results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the costs and success of our marketing efforts, and our ability to promote our brand; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance on key personnel and our ability to identify, recruit and retain skilled personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to effectively manage our growth; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to compete effectively with existing competitors and new market entrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties and other factors that are in some cases beyond our control. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#8220;Risk Factors&#8221; in our most recent annual report on Form 10-K, as well as any subsequent filings with the SEC incorporated by reference into this prospectus supplement. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus supplement together with the documents we have filed with the SEC that are incorporated by reference herein, and any free writing prospectus that we may authorize for use in connection with a specific offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. We do not assume any obligation to update any forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement or the applicable document incorporated by reference herein, as the case may be. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may announce material business and financial information to our investors using our investor relations website (https://ir.mindmed.co). We therefore encourage investors and others interested in our company to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into this prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:480pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are filing this prospectus supplement to permit the selling stockholders to resell their common shares as described herein. We are not selling any common shares under this prospectus supplement and we will not receive any proceeds from the sale or other disposition of the common shares held by the selling stockholders. The selling stockholders will receive all of the proceeds from the sale of such common shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders will pay any discounts, commissions, fees of underwriters, selling brokers or dealer managers and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the common shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the common shares covered by this prospectus supplement, including, without limitation, all registration and filing fees, printing fees, Nasdaq Stock Market LLC listing fees and fees and expenses of our counsel and our accountants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sSEST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">SELLING STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We have prepared this prospectus supplement to allow the selling stockholders to offer and sell from time to time up to 8,000,000 common shares. For additional information regarding the issuance of such common shares, see the section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Description of the Transaction&#8221; above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The number of common shares beneficially owned prior to the offering by the selling stockholders in the table below is based on information supplied to us by the selling stockholders, with beneficial ownership determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to the common shares. This information does not necessarily indicate beneficial ownership for any other purpose. The&#160;percentage of beneficial ownership after this offering is based on 73,321,737 common shares outstanding as of October&#160;17, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may sell some, all or none of the common shares offered by this prospectus supplement from time to time. We do not know how long the selling stockholders will hold the common shares covered hereby before selling them and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any common shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">In addition, since the date on which the selling stockholders provided the information, the selling stockholders may have sold, transferred or otherwise disposed of all or a portion of the common shares in transactions exempt from the registration requirements of the Securities Act. Any changed information given to us by the selling stockholders will be set forth in prospectus supplements, post-effective amendments or in filings we make with the SEC under the Exchange Act, which are incorporated by reference in this prospectus, if and when necessary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">As used in this prospectus, the term &#8220;selling stockholders&#8221; includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a prospectus supplement, and its donees, pledgees, assignees, transferees, distributees and successors-in-interest that receive such common shares in any non-sale transfer after the date of this prospectus supplement. </font>
        </div>
        <table style="width:459.72pt;height:118pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:199pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned Prior </font>
                <br >
                <font style="letter-spacing:-0.16pt;">to Offering</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned After </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:199pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Selling Stockholder</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registered for </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Sale Hereby</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:199pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Deep Track Biotechnology Master Fund, LTD</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(1)</font> </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">7,065,099 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.14<font style="position:absolute;">% </font></td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,000,000 </td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3,065,099 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.96<font style="position:absolute;">% </font></td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:199pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Commodore Capital Master LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font> </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">7,693,859 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.99<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">4,000,000</td>
            <td style="padding:0pt;padding-left:7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5,428,775 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.89<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The number of shares beneficially owned prior to this offering includes 4,000,000 common shares underlying a warrant for common shares owned by this Selling Stockholder. Under the terms of such warrant, the holder may not exercise the warrant to the extent such exercise would cause such holder, together with its affiliates, to beneficially own a number of common shares which would exceed 9.99% of the number of common shares outstanding following such exercise (the &#8220;Ownership Cap&#8221;). Upon 61&#160;days&#8217; advance written notice to us, the holder of such warrant may from time to time increase or decrease the Ownership Cap&#160;percentage up to 19.99%. Deep Track Capital, LP (the &#8220;Deep Track Investment Manager&#8221;) serves as the investment manager to Deep Track Biotechnology Master Fund&#160;Ltd. (the &#8220;Deep Track Master Fund&#8221;) and may be deemed to beneficially own such shares. Deep Track Capital GP, LLC (the &#8220;Deep Track General Partner&#8221;) is the General Partner of the Deep Track Investment Manager. David Kroin is the Chief Investment Officer of the Deep Track Investment Manager and managing member of the Deep Track General Partner and may be deemed to beneficially own such shares. The business address of the Deep Track Master Fund, the Deep Track Investment Manager, the Deep Track General Partner and Mr.&#160;Kroin is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:168pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The number of shares beneficially owned prior to this offering includes 3,693,859 common shares underlying warrants for common shares owned by this Selling Stockholder. Under the terms of such warrants, the holder may not exercise the warrants to the extent such exercise would cause such holder, together with its affiliates, to beneficially own a number of common shares which would exceed the Ownership Cap. Upon 61&#160;days&#8217; advance written notice to us, the holder of such warrants may from time to time increase or decrease the Ownership Cap&#160;percentage up to 19.99%. The number of shares beneficially owned prior to this offering does not include 1,734,916 common shares underlying such warrants as a result of the Ownership Cap and the 61&#160;days&#8217; advance notice provision. The number of shares beneficially owned after this offering includes 1,428,775 common shares underlying a warrant for common shares owned by this Selling Stockholder. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Relationship with Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders have not had any material relationship with us or any of our predecessors or affiliates, within the past three&#160;years, except as hereinafter described. As discussed in greater detail above under the section entitled &#8220;Prospectus Summary&#8201;&#8212;&#8201;Description of the Transaction,&#8221; on March&#160;7, 2024, we entered into the Securities Purchase Agreement with the selling stockholders, pursuant to which we issued an aggregate of 12,500,000 Private Placement Shares at a price of $6.00 per share in the Private Placement. In connection with the Private Placement, we also entered into the Registration Rights Agreement. On October 17, 2024, we entered into the Exchange Agreement with the selling stockholders pursuant to which we exchanged an aggregate of 8,000,000 common shares purchased by the selling stockholders in the Private Placement for Exchange Warrants to purchase an aggregate of 8,000,000 Exchange Shares. In connection with entering into the Exchange Agreement, we also entered into an amendment to the Registration Rights Agreement, pursuant to which we have agreed to register the resale of the Exchange Shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On August&#160;9, 2024, we entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an underwritten public offering (the &#8220;Public Offering&#8221;) of (i)&#160;9,285,511 common shares and (ii)&#160;to one of the selling stockholders, a pre-funded warrant to purchase 1,428,775 common shares. Such pre-funded warrant was sold at an offering price of $6.999 per pre-funded warrant, which represented the per share public offering price for the common shares purchased in the Public Offering less a $0.001 per share exercise price for each such pre-funded warrant. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders of the common shares and any of their pledgees, assignees, donees, transferees or other successors-in-interest (each, a &#8220;selling stockholder,&#8221; and collectively, the &#8220;selling stockholders&#8221;), may, from time to time, sell, transfer or otherwise dispose of any or all of their common shares covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the common shares are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more of the following methods when selling common shares: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">block trades in which the broker-dealer will attempt to sell the common shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to or through underwriters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an exchange distribution in accordance with the rules of the applicable exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">privately negotiated transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">settlement of short sales entered into after the effective date of the registration statement of which this prospectus supplement is a part; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such common shares at a stipulated price per security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through the distribution of the common shares by any selling stockholder to its partners, members or stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">directly to one or more purchasers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through delayed delivery requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by pledge to secured debts and other obligations or any transfer upon the foreclosure under such pledges; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a combination of any such methods of sale; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other method permitted pursuant to applicable law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders may also sell common shares under Rule&#160;144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus supplement. The common shares have not been qualified for distribution in Canada, and may not be offered or sold in Canada during the course of their distribution except pursuant to a Canadian prospectus or a prospectus exemption. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of common shares, from the purchaser) in amounts to be negotiated, but, except as set forth in any supplement to this prospectus supplement, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of the common shares or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common shares in the course of hedging the positions they assume. The selling stockholders may also sell common shares short and deliver these common shares to close out their short positions, or loan or pledge the common shares to broker-dealers that in turn may sell these common shares. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative common shares which require the delivery to such broker-dealer or other financial institution of common shares offered by this prospectus supplement, which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:200pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">common shares such broker-dealer or other financial institution may resell pursuant to this prospectus supplement (as supplemented to reflect such transaction). The selling stockholders also may transfer the common shares in other circumstances in which the transferees, pledgees, donees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The selling stockholders and any broker-dealers or agents that are involved in selling the common shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the common shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The selling stockholders have informed the Company that they do not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the common shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are required to pay certain fees and expenses incurred by us incident to the registration of the common shares. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to keep this prospectus supplement effective until the earlier of (i)&#160;the date on which the common shares may be resold by the selling stockholders without regard to any volume or manner-of-sale limitations by reason of Rule&#160;144 and without the requirement for us to be in compliance with the current public information requirement under Rule&#160;144, and (ii)&#160;all of the common shares have been sold pursuant to this prospectus supplement or Rule&#160;144 under the Securities Act or any other rule of similar effect. The resale common shares will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the common shares covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale of common shares may not simultaneously engage in market making activities with respect to the common shares for the applicable restricted period, as defined in Regulation&#160;M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation&#160;M, which may limit the timing of purchases and sales of the common shares by the selling stockholders or any other person. We will make copies of this prospectus supplement available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus supplement to each purchaser at or prior to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sLEMA">&#8203;</a><a name="sEXP">&#8203;</a><a name="sWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:124pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the common shares in respect of which this prospectus supplement is being delivered and certain legal matters with respect to Canadian law will be passed upon by Osler, Hoskin &amp; Harcourt LLP, Vancouver, Canada. Certain matters in respect of U.S. securities laws may be opined upon by Hogan Lovells US LLP. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Mind Medicine (MindMed) Inc. as of December&#160;31, 2023 and 2022, and for each of the&#160;years in the two year period ended December&#160;31, 2023, have been incorporated by reference herein and in the registration statement of which this prospectus supplement is a part in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the common shares being registered under this prospectus supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on information contained in this prospectus supplement or incorporated by reference into this prospectus supplement. We have not authorized any person to provide you with different information. The common shares are not being offered in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the common shares offered by this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&#8217;s website at http://www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We make available free of charge on our website at https://mindmed.co our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. Please note, however, that we have not incorporated any other information by reference from our website, other than the documents listed under the heading &#8220;Incorporation of Certain Information by Reference.&#8221; In addition, you may request copies of these filings at no cost by writing or telephoning us at the following address or telephone number: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mind Medicine (MindMed) Inc.</font>
          <br >
          <font style="letter-spacing:0.2pt;">Attention: Corporate Secretary</font>
          <br >
          <font style="letter-spacing:0.2pt;">One World Trade Center, Suite 8500,</font>
          <br >
          <font style="letter-spacing:0.2pt;">New York, New York 10007</font>
          <br >
          <font style="letter-spacing:0.2pt;">Telephone: (212) 220-6633 </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="sIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to another document that we have filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this prospectus supplement. Information in this prospectus supplement supersedes information incorporated herein by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement. We incorporate by reference into this prospectus supplement, the accompanying prospectus and the registration statement of which this prospectus supplement is a part the information and documents listed below that we have filed with the SEC (Commission File No. 001-40360): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, filed with the SEC</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">on February&#160;28, 2024</a> (the &#8220;2023 Form 10-K&#8221;) including portions of our <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1813814/000110465924052454/tm2412544-1_def14a.htm">Definitive Proxy Statement on Schedule&#160;14A, filed with the SEC on April&#160;26, 2024,</a> that are incorporated by reference into Part&#160;III of such Annual Report on Form 10-K; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the quarterly periods ended March&#160;31, 2024 and June&#160;30, 2024, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024055681/mnmd-20240331.htm">May&#160;8, 2024</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024095753/mnmd-20240630.htm">August&#160;13, 2024</a>, respectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K (other than portions thereof furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits accompanying such reports that relate to such items), filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000119312524061361/d682854d8k.htm">March&#160;7, 2024,</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000119312524064380/d787577d8k.htm">March&#160;11, 2024,</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024039484/mnmd-20240401.htm">April&#160;1, 2024,</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024071953/mnmd-20240610.htm">June&#160;11, 2024,</a> <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024075317/mnmd-20240620.htm">June&#160;20, 2024</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000110465924076037/tm2416299d1_8k.htm">June&#160;28, 2024</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000110465924088108/tm2420790d4_8k.htm">August&#160;12, 2024;</a> and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common shares, which is contained in our registration statement on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1813814/000110465921053876/tm2112540d1_8a12b.htm">Form&#160;8-A, filed with the SEC on April&#160;22, 2021</a> under the Exchange Act, as updated by <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1813814/000095017024021656/mnmd-ex4_1.htm">Exhibit&#160;4.1</a> to our 2023 Form 10-K, including any amendment or report filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All reports and other documents subsequently filed by us pursuant to Sections&#160;13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination or completion of the offering of securities under this prospectus supplement shall be deemed to be incorporated by reference into this prospectus supplement and to be a part hereof from the date of filing such reports and other documents. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus supplement but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Mind Medicine (MindMed) Inc., Attention: Corporate Secretary, One World Trade Center, Suite 8500, New York, New York 10007. Our phone number is (212) 220-6633. You may also view the documents that we file with the SEC and incorporate by reference in this prospectus supplement on our corporate website at https://mindmed.co. The information on our website is not incorporated by reference and is not a part of this prospectus supplement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_mindmed-4c.jpg" alt="[MISSING IMAGE: lg_mindmed-4c.jpg]" height="53" width="240" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Shares </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Debt Securities </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Units</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:8.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, may offer to the public from time to time in one or more series or issuances and on terms that we will determine at the time of the offering: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our common shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">warrants to purchase our common shares and/or debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">debt securities consisting of debentures, notes or other evidences of indebtedness; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">units consisting of a combination of the foregoing securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any combination of these securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides a general description of the securities that we, or any selling security holders, may offer. Each time that we, or any selling security holders, as applicable, offer securities under this prospectus, we, or any selling security holders, as applicable, will provide the specific terms of the securities offered, including the public offering price, in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. Any prospectus supplement and free writing prospectus may add to, update or change information contained or incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The securities may be sold by us, or any selling security holders, as applicable, to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. If any underwriters are involved in the sale of the securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts, commissions and purchase options will be set forth in the applicable prospectus supplement. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this prospectus and the comparable section of any applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common shares are traded on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the ticker symbol &#8220;MNMD&#8221;. On June&#160;25, 2024, the last reported sale price of our common shares was $7.07. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings. See &#8220;Implications of Being an Emerging Growth Company.&#8221; </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. RISKS ASSOCIATED WITH AN INVESTMENT IN OUR SECURITIES WILL BE DESCRIBED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND CERTAIN OF OUR FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION INCORPORATED BY REFERENCE INTO THIS PROSPECTUS, AS DESCRIBED UNDER &#8220;RISK FACTORS&#8221; ON PAGE <a href="#tRIFA">8</a>.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You should read this entire prospectus, any applicable prospectus supplement and free writing prospectus, together with additional information described under the heading &#8220;Where You Can Find More Information&#8221; before you invest in our securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus is June 28, 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a><a name="GoBack">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:341pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:250pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">1</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIAO"><font style="letter-spacing:0.2pt;">MARKET, INDUSTRY AND OTHER DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMIAO">3</a></font> <a href="#tMIAO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">THE COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">4</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">8</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">9</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSESE"><font style="letter-spacing:0.2pt;">SELLING SECURITYHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSESE">10</a></font> <a href="#tSESE"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">11</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tGDOO"><font style="letter-spacing:0.2pt;">GENERAL DESCRIPTION OF OUR SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tGDOO">14</a></font> <a href="#tGDOO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOC"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR COMMON SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOC">15</a></font> <a href="#tDOOC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOW">16</a></font> <a href="#tDOOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOD"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOD">18</a></font> <a href="#tDOOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOU"><font style="letter-spacing:0.2pt;">DESCRIPTION OF OUR UNITS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOOU">23</a></font> <a href="#tDOOU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">24</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">INCORPORATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">24</a></font> <a href="#tIBR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">24</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">25</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we, or selling security holders, as applicable, may offer to sell any of the securities, or any combination of the securities, described in this prospectus, in each case in one or more offerings from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides you only with a general description of the securities that we, or any selling security holders, as applicable, may offer in one or more offerings from time to time. Each time securities are sold under this shelf registration statement, we will provide an accompanying prospectus supplement or free writing prospectus that will contain specific information about the terms of those securities and the terms of that offering. The accompanying prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and any accompanying prospectus supplement or free writing prospectus, you should rely on the information in the accompanying prospectus supplement or free writing prospectus. You should read both this prospectus and any accompanying prospectus supplement or free writing prospectus, including all documents incorporated by reference herein and therein, together with the additional information described under the heading &#8220;Where You Can Find More Information&#8221; below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information provided in or incorporated by reference into this prospectus or in any accompanying prospectus supplement or free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference into this prospectus and any accompanying prospectus supplement or free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference into this prospectus or an accompanying prospectus supplement or free writing prospectus. This prospectus and the accompanying prospectus supplement or free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and the accompanying prospectus supplement or free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and the accompanying prospectus supplement or free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement or free writing prospectus is delivered or securities are sold on a later date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise indicated or unless the context otherwise requires, references to &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to Mind Medicine (MindMed) Inc. and its consolidated subsidiaries and references to dollars or dollar amounts refer to U.S. dollars or U.S. dollar amounts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus may contain references to our trademarks and trade names and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> or &#8482; symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us or our business by, any other companies.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, any applicable prospectus supplement, the documents that we incorporate by reference herein and therein, contain, and any free writing prospectus that we authorize for use may contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, progress and results of our investigational programs for MM120, a proprietary, pharmaceutically optimized form of lysergide D-tartrate, MM402, also referred to as R(-)-MDMA (together, our &#8220;lead product candidates&#8221;) and any other product candidates (together with our lead product candidates, our &#8220;product candidates&#8221;), including statements regarding the timing of initiation and completion of trials or studies and related preparatory work, the period during which the results of the trials will become available and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance on the success of our investigational MM120 product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, scope or likelihood of regulatory filings and approvals and our ability to obtain and maintain regulatory approvals for product candidates for any indication; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the size of the eligible patient populations for our lead product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify third-party treatment sites to conduct our trials and our ability to identify and train appropriate qualified healthcare practitioners to administer our treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to implement our business model and our strategic plans for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify new indications for our lead product candidates beyond our current primary focuses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify, develop or acquire digital technologies to enhance our administration of our product candidates, if they should become approved and commercialized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to achieve profitability and then sustain such profitability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercialization, marketing and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the pricing, coverage and reimbursement of our lead product candidates, if approved and commercialized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance and clinical utility of our lead product candidates, in particular, and controlled substances, in general; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">future investments in our business, our anticipated capital expenditures and our estimates regarding our capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish or maintain collaborations or strategic relationships or to obtain additional funding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding potential benefits of our lead product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain effective patent rights and other intellectual property protection for our product candidates, and to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">infringement or alleged infringement on the intellectual property rights of third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">legislative and regulatory developments in the United States, including individual states, Canada, the United Kingdom, and other jurisdictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effectiveness of our internal control over financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">actions of activist shareholders against us have been and could be disruptive and costly and may result in litigation and have an adverse effect on our business and share price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of adverse global economic conditions, including public health crises (such as the COVID-19 pandemic), geopolitical conflicts, fluctuations in interest rates, supply-chain disruptions and inflation, on our financial condition and operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Loan and Security Agreement with K2 HealthVentures LLC, as administrative agent and Canadian collateral agent for lenders thereunder, and Ankura Trust Company, LLC, as collateral trustee, contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding our future revenue, expenses and other operating results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the costs and success of our marketing efforts, and our ability to promote our brand; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance on key personnel and our ability to identify, recruit and retain skilled personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to effectively manage our growth; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to compete effectively with existing competitors and new market entrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties and other factors that are in some cases beyond our control. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We will discuss in greater detail many of these risks under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement, and in any free writing prospectus, and in our most recent annual report on Form&#160;10-K, as well as any subsequent filings with the SEC incorporated by reference into this prospectus. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus or the applicable document incorporated by reference herein, as the case may be. And, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may announce material business and financial information to our investors using our investor relations website (https://ir.mindmed.co/). We therefore encourage investors and others interested in our company to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tMIAO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET, INDUSTRY AND OTHER DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, and any applicable prospectus supplement or free writing prospectus and the documents incorporated by reference herein and therein, contain market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tTHCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including MM120 and MM402, our lead product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of generalized anxiety disorder (&#8220;GAD&#8221;). We have also evaluated MM120 in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;). In December&#160;2023, we announced positive topline results from our Phase&#160;2b clinical trial of MM120 for the treatment of GAD. The trial met its primary endpoint, with MM120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety rating scale compared to placebo at Week 4. In January&#160;2024, we announced that our Phase&#160;2a trial of a sub-perceptual dose of MM120 in ADHD did not meet its primary endpoint. In conjunction with the findings from our clinical trial of MM120 in GAD, we believe that these results support the critical role of perceptual effects of MM120 in mediating a clinical response. In March&#160;2024, we announced that the FDA granted breakthrough designation to our MM120 program for the treatment of GAD. We also announced in March&#160;2024 that our Phase&#160;2b trial of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12. We intend to work closely with the FDA to finalize our Phase&#160;3 development program for MM120 in GAD. On June 20, 2024, we announced the completion of our End-of-Phase&#160;2 meeting with the FDA, supporting the advancement of MM120 into pivotal trials for the treatment of adults with GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet in GAD in the second half of this year and plan to share additional details on the design of our pivotal program in the coming months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our second lead product candidate, MM402, also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (&#8220;MDMA&#8221;), which we are developing for the treatment of autism spectrum disorder (&#8220;ASD&#8221;). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrated its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggests that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. In the third quarter of 2022, our collaborator, University Hospital Basel (&#8220;UHB&#8221;) in Switzerland, began conducting a Phase&#160;1 investigator-initiated trial (&#8220;IIT&#8221;) of R(-)-MDMA, S(+)-MDMA and R/S-MDMA in healthy volunteers to compare the tolerability, pharmacokinetics and acute subjective, physiological and endocrine effects of the three molecules. On June&#160;6, 2024, UHB presented topline data from the trial at the Interdisciplinary Conference on Psychedelic Research in The Netherlands. The presentation noted that the trial indicates that R(-)-MDMA, S(+)-MDMA and R/S-MDMA induced overall similar qualitative subjective and adverse effects when dosed equivalently. The presentation also noted that S(+)-MDMA may have slightly greater stimulant like properties than R/S-MDMA and R(-)-MDMA. The pharmacokinetic findings from the trial indicate that R(-)-MDMA, but not S(+)-MDMA, inhibits the Cytochrome P450 2D6 enzyme (CYP2D6), which is the primary metabolic pathway for MDMA inactivation, and thereby its own inactivation and that of S(+)-MDMA when administered as R/S-MDMA. In addition, we have initiated our first clinical trial of MM402, a single-ascending dose trial in adult healthy volunteers in the fourth quarter of 2023. This Phase&#160;1 clinical trial is intended to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM402. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beyond our clinical stage product candidates, we are pursuing a number of programs, primarily through external collaborations, through which we seek to expand our drug development pipeline and broaden the potential applications of our lead product candidates. These research and development programs </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">include non-clinical, pre-clinical and human clinical trials and IITs of additional product candidates and research compounds with our collaborators. Our external research programs include a broad multi-year exclusive research partnership with UHB in Switzerland. Under the partnership, we have exclusive worldwide rights to data, compounds and patent rights associated with UHB&#8217;s research on lysergide and a number of additional compounds, including data from preclinical studies and clinical trials investigating the effects of lysergide in patient populations and healthy volunteers. We also have an ongoing partnership agreement with MindShift Compounds AG to develop next-generation compounds utilizing the molecular backbone of classical psychedelics and empathogens. In addition, we have in the past and will continue to engage in other relevant research collaborations to support our ongoing development efforts and potential additions to our pipeline. Our research partnerships and IITs facilitate the advancement of our early-stage pipeline and support the potential identification of product candidates for additional company-sponsored drug development programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our drug development program is complemented by digital medicine projects to develop products intended to help facilitate the adoption and scalability of our product candidates, if and when they are approved. Our digital medicine projects and product roadmaps, and strategies, and investments are based on the projected development and commercialization strategies of our product candidates, with timelines and investments for each project contingent on the progression of the related drug program. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our business is premised on a growing body of research supporting the use of novel psychoactive compounds to treat a myriad of brain health disorders. For all product candidates, we intend to proceed through research and development, and with marketing of the product candidates that may ultimately be approved pursuant to the regulations of the FDA and the legislation in other jurisdictions. This entails, among other things, conducting clinical trials with research scientists, using internal and external clinical drug development teams, producing and supplying drugs according to current Good Manufacturing Practices, and conducting all trials and development in accordance with the regulations of the FDA, and other legislation in other jurisdictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Product Candidate Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the status of our portfolio of product candidates: </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="bc_pipeline-4c.jpg" alt="[MISSING IMAGE: bc_pipeline-4c.jpg]" height="305" width="608" >
        </div>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12-week Durability Data from Phase&#160;2b Study of MM120 for GAD</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;7, 2024, we announced that the FDA granted breakthrough designation to our MM120 program for the treatment of GAD. We also announced that our Phase&#160;2b trial of MM120 in GAD met its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MM120 100&#181;g&#8201;&#8212;&#8201;the dose with optimal clinical activity observed in the trial&#8201;&#8212;&#8201;demonstrated a 7.7-point improvement over placebo at Week 12 (-21.9 MM120 vs. <font style="white-space:nowrap;">-14.2</font> placebo; p&lt;0.003 Cohen&#8217;s d=0.81), with a 65% clinical response rate and a 48% clinical remission rate sustained to Week 12. Clinical Global Impressions -Severity (CGI-S) scores on average improved from 4.8 to 2.2 in the 100&#181;g dose group, representing a two-category shift from &#8216;markedly ill&#8217; to &#8216;borderline ill&#8217; at Week 12 (p&lt;0.004). This clinical activity was rapid, observed as early as trial day 2, and durable with further improvements observed in mean HAM-A or CGI-S scores between Weeks 4 and 12. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the Phase&#160;2b trial, known as MMED008, MM120 was generally well-tolerated with most adverse events rated as mild to moderate, transient, occurring on dosing day, and being consistent with expected acute effects of the trial drug. The most common adverse events, with at least 10% incidence on dosing day in the 100&#181;g dose group, included illusion, nausea, headache, hallucination, euphoric mood, anxiety, mydriasis, hyperhidrosis, paresthesia, fatigue, blood pressure increase, abnormal thinking, and altered state of consciousness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to treatment with MM120, study participants were clinically tapered and then washed out from any anxiolytic or antidepressant treatments and did not receive any form of study-related psychotherapy for the duration of their participation in the study. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">March Financings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Underwritten Offering</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;7, 2024, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink Partners LLC and Cantor Fitzgerald &amp; Co., as representatives of the underwriters named therein (the &#8220;Underwriters&#8221;), in connection with the issuance and sale by us in an underwritten offering (the &#8220;Offering&#8221;) of 16,666,667 of our common shares at an offering price of $6.00 per share, less underwriting discounts and commissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The net proceeds from the Offering were approximately $93.5&#160;million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The Offering closed on March&#160;11, 2024. We intend to use the net proceeds from the Offering for (i)&#160;the research and development of our product candidates and (ii)&#160;working capital and general corporate purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Offering was made pursuant to our shelf registration statements on Form S-3 (File Nos. 333-264648 and 333-277726), together, the &#8220;Registration Statements&#8221;), which were filed with the SEC on May&#160;4, 2022 and March&#160;7, 2024, respectively, and declared effective by the SEC or automatically became effective on May&#160;16, 2022 and March&#160;7, 2024, respectively, and a related base prospectus, as supplemented by a prospectus supplement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Private Placement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Also on March&#160;7, 2024, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Investors agreed to purchase, and we agreed to sell 12,500,000 of our common shares (the &#8220;Private Placement Shares&#8221;), at a price of $6.00 per share, in a private placement transaction (the &#8220;Private Placement&#8221;). The Private Placement Shares were issued to the Investors pursuant to an exemption from the registration requirements of the Securities afforded by Section&#160;4(a)(2) of the Securities Act and/or Rule&#160;506(b) of Regulation&#160;D promulgated thereunder. Pursuant to the terms of the Purchase Agreement, we agreed to register for resale the common shares being issued in the Private Placement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The net proceeds from the Private Placement were approximately $70.1&#160;million, after deducting fees and expenses payable by us. We intend to use the net proceeds from the Private Placement for (i)&#160;the research and development of our product candidates and (ii)&#160;working capital and general corporate purposes. The Private Placement closed on March&#160;11, 2024. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voluntary CBOE Canada Delisting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective April&#160;10, 2024, we voluntarily delisted our common shares from Cboe Canada. Our common shares will continue to trade on Nasdaq under the symbol &#8220;MNMD&#8221;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Departure of CFO and Appointment of new Principal Financial Officer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On May&#160;3, 2024, Schond Greenway&#8217;s employment with the Company as the Chief Financial Officer was terminated without cause, effective immediately. On May&#160;7, 2024, the Board of Directors of the Company appointed Carrie Liao, the Chief Accounting Officer of the Company, to serve as the Company&#8217;s principal financial officer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">End of Phase 2 Meeting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On June 20, 2024, we announced the completion of our End-of-Phase&#160;2 meeting with the FDA, supporting the advancement of MM120 into pivotal trials for the treatment of adults with GAD. We are on schedule to initiate our Phase&#160;3 clinical program for MM120 oral dissolving tablet in GAD in the second half of this year and plan to share additional details on the design of our pivotal program in the coming months. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;) enacted in April&#160;2012, and we will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the first fiscal year in which we have more than $1.235&#160;billion in annual revenue; (2)&#160;the date on which we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by non-affiliates; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;following the fifth anniversary of the date of the first sale of our common equity securities under an effective registration statement under the Securities Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the Province of British Columbia. Our wholly owned subsidiary, Mind Medicine, Inc. (&#8220;MindMed US&#8221;), was incorporated in Delaware. Prior to February&#160;27, 2020, our operations were conducted through MindMed US. Our office is located at One World Trade Center, Suite&#160;8500, New York, New York 10007, and our telephone number at that location is (212) 220-6633. Our website address is https://mindmed.co/. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:440pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities and any free writing prospectus will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#8220;Risk Factors&#8221; in the applicable prospectus supplement and any free writing prospectus, together with all of the other information contained or incorporated by reference into the prospectus supplement or any free writing prospectus or appearing or incorporated by reference into this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K, our most recent Quarterly Report on Form 10-Q, each filed with the SEC, and in our other filings with the SEC, including our future reports to be filed with the SEC, all of which are incorporated herein by reference as described in this prospectus under the heading &#8220;Where You Can Find More Information&#8221;. The risks and uncertainties we have described in such documents are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise provided in the applicable prospectus supplement relating to a specific offering, we intend to use the net proceeds from the sale of securities by us under this prospectus and any applicable prospectus supplement or free writing prospectus for (i)&#160;the research and development of our product candidates and (ii)&#160;working capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire additional businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any future acquisitions as of the date of this prospectus. Additional information on the use of net proceeds from the sale of securities by us under this prospectus may be set forth in the accompanying prospectus supplement or free writing prospectus relating to the specific offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSESE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:492pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELLING SECURITYHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire, our securities. Such selling securityholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The purchasers of our securities, as well as their transferees, pledgees, donees, or successors, all of whom we refer to as &#8220;selling securityholders,&#8221; may from time to time offer and sell the securities pursuant to this prospectus and any applicable prospectus supplement or free writing prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement or free writing prospectus will set forth the name of each of the selling securityholders and the number of our common shares or other relevant securities beneficially owned by such selling securityholders that are covered by such prospectus supplement or free writing prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may sell the securities being offered by this prospectus from time to time pursuant to public offerings, negotiated transactions, block trades, &#8220;at the market offerings&#8221; within the meaning of Rule&#160;415(a)(4) of the Securities Act, into an existing trading market, at a fixed price or prices, which may be changed, at prevailing market prices, at prices related to such prevailing market prices, at negotiated prices or a combination of any of these methods. We, or any selling security holders, as applicable, may sell the securities being offered by this prospectus to or through underwriters, dealers, agents, remarketing firms or other third parties, or directly to one or more purchasers or through a combination of any of these methods of sale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement or supplements (and any free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities being offered by this prospectus, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name or names of the underwriters, dealers, agents or remarketing firm, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the securities are to be offered through the selling efforts of brokers or dealers, the plan of distribution and the terms of any agreement, arrangement or understanding entered into with broker(s) or dealer(s) prior to the date of the applicable prospectus supplement or supplements, and, if known, the identity of any broker(s) or dealer(s) who will participate in the offering and the amount to be offered through each; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we, or any selling security holders, as applicable, will receive from the sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if any of the securities being registered are to be offered otherwise than for cash, the general purposes of the distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution and by whom they are to be borne; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any public offering price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any delayed delivery arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any options under which underwriters may purchase additional securities from us, or any selling security holders, as applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any discounts, commissions or concessions allowed or reallowed or paid to dealers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the identity and relationships of any finders, if applicable; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any securities exchange or market on which the securities may be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only underwriters named in the applicable prospectus supplement will be underwriters of the securities offered by the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We, or any selling security holders, as applicable, may offer the securities being offered by this prospectus to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless otherwise indicated in the applicable prospectus supplement, subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the applicable prospectus supplement, other than securities covered by any purchase option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We, or any selling security holders, as applicable, may use underwriters, dealers or agents with whom we, or any selling security holders, as applicable, have a material relationship. We will describe in the applicable prospectus supplement, naming the underwriter, dealer or agent, the nature of any such relationship. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we, or any selling security holders, as applicable, offer and sell securities through a dealer, we, or any selling security holders, as applicable, or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The name of the dealer and the terms of the transaction will be set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may sell securities directly or through agents we, or any selling security holders, as applicable, designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we, or any selling security holders, as applicable, will pay to the agent in the applicable prospectus supplement. Unless the applicable prospectus supplement states otherwise, such agent will act on a best-efforts basis for the period of its appointment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may use a remarketing firm to offer the securities being offered by this prospectus in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own account or as agents for us, or any selling security holders, as applicable. These remarketing firms will offer or sell the securities pursuant to the terms of the securities. The applicable prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us, or any selling security holders, as applicable, and will describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may sell securities directly to one or more purchasers without using underwriters, dealers or agents. Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us, or any selling security holders, as applicable, and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us, or any selling security holders, as applicable, at the public offering price set forth in the applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we, or any selling security holders, as applicable, must pay for solicitation of these contracts in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may provide underwriters, dealers, agents or remarketing firms with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the underwriters, dealers, agents or remarketing firms may make with respect to these liabilities. Underwriters, dealers, agents or remarketing firms or their respective affiliates, may engage in transactions with, or perform services for, us, or any selling security holders, as applicable, in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All securities we, or any selling security holders, as applicable, may offer, other than our common shares, will be new issues of securities with no established trading market. Any underwriter may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We, or any selling security holders, as applicable, cannot guarantee the liquidity of the trading markets for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any underwriter may engage in purchase options, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation&#160;M under the Exchange Act. Purchase options involve sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the purchase option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:464pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters that are qualified market makers on Nasdaq may engage in passive market making transactions in our common shares on Nasdaq in accordance with Regulation&#160;M under the Exchange Act, during the business day prior to the pricing of an offering, before the commencement of offers or sales of our common shares. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tGDOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:450pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">GENERAL DESCRIPTION OF OUR SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may offer and sell, at any time and from time to time: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our common shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">warrants to purchase our common shares and/or debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">debt securities consisting of debentures, notes or other evidences of indebtedness; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">units consisting of a combination of the foregoing securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any combination of these securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of any securities we offer will be determined at the time of sale. We may issue debt securities that are exchangeable for and/or convertible into our common shares or any of the other securities that may be sold under this prospectus. When particular securities are offered by us, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF OUR COMMON SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description sets forth certain material terms and provisions of our common shares that are registered under Section&#160;12 of the Exchange Act. The following description of our common shares is intended as a summary only and is qualified in its entirety by reference to our notice of articles and our amended and restated articles, and any amendments thereto (the &#8220;Articles&#8221;), each of which are filed as exhibits to our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a>, which is incorporated by reference herein, and to the applicable provisions of the Business Corporations Act (British Columbia) (the &#8220;BCBCA&#8221;).</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are authorized to issue an unlimited number of our common shares, no par value per share. As of June&#160;25, 2024, there were 72,075,076 of our common shares outstanding. As of June&#160;25, 2024, we had approximately 78 shareholders of record. This figure does not reflect the number of beneficial owners of our common shares as a single shareholder of record often holds shares in nominee name (also referred to as, in &#8220;street name&#8221;) on behalf of multiple beneficial owners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of our common shares have no preemptive or other subscription rights, and there are no conversion rights or redemption or sinking fund provisions with respect to such common shares. All our outstanding common shares are, and our common shares when issued will be, fully paid and nonassessable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Voting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The holders of our common shares are entitled to one vote per common share on all matters to be voted on by our shareholders. A quorum will be present if at least two shareholders holding in the aggregate at least 33</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">1</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the issued and outstanding common shares entitled to be voted at a meeting of shareholders are present at the meeting or represented by proxy, irrespective of the number of persons actually present at the meeting of shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The holders of our common shares are entitled to receive dividends as and when declared by our board of directors (the &#8220;Board&#8221;). We have not declared or paid cash dividends on our share capital since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our Board after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments and other factors that our Board deems relevant. In addition, our ability to pay cash dividends on our share capital in the future may be limited by the terms of any future debt or we issue or any credit facilities we enter into. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Liquidation, Subdivision, or Combination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of our liquidation, dissolution or winding-up or other distribution of our assets among our shareholders, the holders of our common shares are entitled to share </font><font style="font-style:italic;letter-spacing:0.2pt;">pro&#160;rata</font><font style="letter-spacing:0.2pt;"> in the distribution of the balance of our assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advance Notice Procedures and Shareholder Proposals</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the BCBCA, shareholders may make proposals for matters to be considered at the annual general meeting of shareholders. Such proposals must be sent to us in advance of any proposed meeting by delivering a timely written notice in proper form to our registered office in accordance with the requirements of the BCBCA. The notice must include information on the business the shareholder intends to bring before the meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our Articles require that shareholders provide us with advance notice of their intention to nominate any persons, other than those nominated by management, for election to our board of directors at a meeting of shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These provisions could have the effect of delaying the nomination of certain persons for director that are favored by the holders of a majority of our outstanding voting securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common shares is Computershare Investor Services Inc., with an address of 510 Burrard Street, 3rd Floor, Vancouver, British Columbia V6C 3B9. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common shares are listed on Nasdaq under the trading symbol &#8220;MNMD&#8221;. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF OUR WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, or any selling security holders, as applicable, may offer and sell warrants to purchase our common shares and/or debt securities in one or more series together with other securities or separately, as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we, or any selling security holders, as applicable, may offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the specific designation and aggregate number of the warrants, and the price at which we, or any selling security holders, as applicable, will offer such warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency or currency&#160;units in which the offering price, if any, and the exercise price are payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation, amount and terms of the securities purchasable upon exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the exercise price for our common shares and the number of common shares to be received upon exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon exercise of the warrants and a description of that series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the warrants are to be sold separately or with other securities as parts of&#160;units; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any material Canadian federal or provincial income tax, U.S. federal income tax or other tax considerations applicable to the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the identity of the warrant agent for the warrants, if any, and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange or market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date from and after which the warrants and the common shares and/or debt securities will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">information with respect to book-entry procedures, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the anti-dilution provisions of the warrants, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any redemption, put or call provisions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise of Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:432pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the Province of British Columbia. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF OUR DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section describes the general terms and provisions of the debt securities that we may offer under this prospectus, any of which may be issued as convertible or exchangeable debt securities. We will set forth the particular terms of the debt securities we offer in the applicable prospectus supplement. The extent, if any, to which the following general provisions apply to particular debt securities will be described in the applicable prospectus supplement. You should read the indenture and the applicable prospectus supplement regarding any particular issuance of debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities offered by this prospectus and any accompanying prospectus supplement, if any, under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed or will file a copy of the form of indenture as an exhibit to the registration statement in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of 1939. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent direct, unsecured obligations of our company and will rank equally with all of our other unsecured indebtedness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following descriptions of general terms relating to the debt securities and the indenture under which the debt securities will be issued are summaries only, are qualified in their entirety by reference to the detailed provisions of the indenture and the final form indenture as may be filed with the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the prospectus supplement is delivered: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the aggregate principal amount; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the issue price or prices, expressed as a&#160;percentage of the aggregate principal amount of the debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limit on the aggregate principal amount; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates on which the debt securities will be issued and on which principal of, and premium, if any, is payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates from which interest will accrue, the interest payment date or dates on which interest will be payable and any regular record date for the interest payable, and the basis upon which interest will be calculated if other than that of a 360-day year of twelve 30-day&#160;months; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the place or places where principal and, if applicable, premium and interest, is payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the denominations in which such debt securities may be issuable, if other than a minimum denomination of $2,000 or an integral multiple of $1,000 in excess thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities are to be issuable in the form of certificated debt securities (as described below) or global debt securities (as described below); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal amount of the debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency of denomination; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation of the currency, currencies or currency&#160;units in which payment of principal and, if applicable, premium and interest, will be made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies or currency&#160;units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index, including an index based on a currency or currencies other than in which the debt securities are payable, then the manner in which such amounts will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions, if any, relating to any collateral provided for such debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities will be guaranteed by any person or persons and, if so, the identity of such person or persons, the terms and conditions upon which such debt securities shall be guaranteed and, if applicable, the terms and conditions upon which such guarantees may be subordinated to other indebtedness of the respective guarantors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any addition to or change in the covenants described in this prospectus or in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any events of default, if not otherwise described below under &#8220;Defaults and Notice&#8221;; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if any, for conversion into or exchange for our common shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to other indebtedness of our company; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms of the debt securities of such series. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations that apply to these debt securities in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or&#160;units. If we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or&#160;units in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exchange and/or Conversion Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities which can be exchanged for or converted into our common shares. If we do, we will describe the terms of exchange or conversion in the prospectus supplement relating to such debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer and Exchange</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities that will be represented by either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;book-entry securities,&#8221; which means that there will be one or more global securities registered in the name of a depositary or a nominee of a depositary; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;certificated securities,&#8221; which means that they will be represented by a certificate issued in definitive registered form. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry or certificated securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of a series may be issued in the form of one or more global securities that will be deposited with a depositary or its nominees identified in the prospectus supplement relating to the debt securities. In such a case, one or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal amount of outstanding debt securities of the series to be represented by such global security or securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless and until it is exchanged in whole or in part for debt securities in definitive registered form, a global security may not be registered for transfer or exchange except as a whole by the depositary for such global security to a nominee of the depositary and except in the circumstances described in the prospectus supplement relating to the debt securities. The specific terms of the depositary arrangement with respect to a series of debt securities will be described in the prospectus supplement relating to such series of debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certificated Debt Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you hold certificated debt securities issued under an indenture, you may transfer or exchange such debt securities in accordance with the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or other governmental charge payable in connection with such transfer or exchange. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Protection in the Event of Change of Control</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any provision in an indenture that governs the debt securities covered by this prospectus that includes any covenant or other provision providing for a put or increased interest or otherwise that would afford holders of the debt securities additional protection in the event of a recapitalization transaction, a change of control of our company, or a highly leveraged transaction will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covenants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in this prospectus or the applicable prospectus supplement, the debt securities may not have the benefit of any covenant that limits or restricts our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidation, Merger, Conveyance, Transfer or Lease</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may agree in any indenture that governs the debt securities of any series covered by this prospectus that we will not consolidate with or merge into any other person or convey, transfer or lease (as lessor) our properties and assets as, or substantially as, an entirety to any person, unless such person and such proposed transaction meets various criteria, which we will describe in detail in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Defaults and Notice</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of any series will contain events of default to be specified in the applicable prospectus supplement, which may include, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance of such default for a period of 30&#160;days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the payment of the principal of or any premium on any debt security of that series at its maturity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the deposit of any sinking fund payment, when and as due by the terms of a debt security of that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the performance or breach of any other covenants or agreements in the indenture with respect to the debt securities of such series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">certain events relating to our bankruptcy, insolvency or reorganization. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an event of default with respect to debt securities of any series covered by this prospectus shall occur and be continuing, we may agree that the trustee or the holders of at least 25% in aggregate principal amount of the then outstanding debt securities of such series may declare the principal amount (or, if the debt securities of such series are issued at an original issue discount, such portion of the principal amount as may be specified in the terms of the debt securities of such series) of all debt securities of such series or such other amount or amounts as the debt securities or supplemental indenture with respect to such series may provide, to be due and payable immediately. Any provisions pertaining to events of default and any remedies associated therewith will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any indenture that governs the debt securities covered by this prospectus may require that the trustee under such indenture shall, within 90&#160;days after the occurrence of a default, give to holders of debt securities of any series notice of all uncured and unwaived defaults with respect to such series known to it. However, in the case of a default that results from the failure to make any payment of the principal of, premium, if any, or interest on the debt securities of any series, or in the payment of any sinking or purchase fund installment with respect to debt securities of such series, if any, the trustee may withhold such notice if it in good faith determines that the withholding of such notice is in the interest of the holders of debt securities of such series. Any terms and provisions relating to the foregoing types of provisions will be described in further detail in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any indenture that governs the debt securities covered by this prospectus will contain a provision entitling the trustee to be indemnified by holders of debt securities before proceeding to exercise any trust or power under the indenture at the request of such holders. Any such indenture may provide that the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceedings for any remedy available to the trustee, or of exercising any trust or power conferred upon the trustee with respect to the debt securities of such series. However, the trustee under any such indenture may decline to follow any such direction if, among other reasons, the trustee determines in good faith that the actions or proceedings as directed may not lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial to the holders of the debt securities of such series not joining in such direction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any indenture that governs the debt securities covered by this prospectus may endow the holders of such debt securities to institute a proceeding with respect to such indenture, subject to certain conditions, which will be specified in the applicable prospectus supplement and which may include, that the holders of at least a majority in aggregate principal amount of the debt securities of such series then outstanding make a written request upon the trustee to exercise its power under the indenture, indemnify the trustee and afford the trustee reasonable opportunity to act. Even so, such holders may have an absolute right to receipt of the principal of or premium, if any, and interest when due, to require conversion or exchange of debt securities if such indenture provides for convertibility or exchangeability at the option of the holder and to institute suit for the enforcement of such rights. Any terms and provisions relating to the foregoing types of provisions will be described in further detail in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of the Indenture</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and the trustee may modify any indenture that governs the debt securities of any series covered by this prospectus with or without the consent of the holders of such debt securities, under certain circumstances to be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Defeasance; Satisfaction and Discharge</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement will outline the conditions under which we may elect to have certain of our obligations under the indenture discharged and under which the indenture obligations will be deemed to be satisfied. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regarding the Trustee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will identify the trustee and any relationship that we may have with such trustee, with respect to any series of debt securities, in the prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor of us, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any &#8220;conflicting interest&#8221; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The law governing the indenture and the debt securities will be identified in the prospectus supplement relating to the applicable indenture and debt securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOOU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:106pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF OUR UNITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of the&#160;units that we may offer under this prospectus. Units may be offered independently or together with one or more of the securities that may be offered under this prospectus, in any combination, and may be attached to or separate from those securities. While the terms we have summarized below will generally apply to any future&#160;units that we may offer under this prospectus, we will describe the particular terms of any series of&#160;units that we may offer in more detail in the applicable prospectus supplement. The terms of any&#160;units offered under a prospectus supplement may differ from the terms described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The form of unit agreement, including a form of unit certificate, if any, will describe the terms of the series of&#160;units we may offer under this prospectus. The following summaries of material provisions of the&#160;units, and the unit agreements, are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement applicable to a particular series of&#160;units. We urge you to read the applicable prospectus supplements related to the&#160;units that we sell under this prospectus, as well as the complete unit agreements that contain the terms of the&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units comprised of one or more of the securities that may be offered under this prospectus. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of&#160;units, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and the material terms of the&#160;units and of the securities comprising the&#160;units, including whether, and under what circumstances, those securities may be held or transferred separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rights and obligations of the unit agent, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the material Canadian and U.S. federal income tax considerations applicable to the&#160;units; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any material provisions of the governing unit agreement that differ from those described herein; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any material provisions for the issuance, payment, settlement, transfer or exchange of the&#160;units or of the securities comprising the&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The provisions described in this section, as well as those described under &#8220;Description of Our Common Shares,&#8221; &#8220;Description of Our Debt Securities&#8221; and &#8220;Description of Our Warrants,&#8221; will apply to each unit and to any common shares, debt securities or warrants included in each unit, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Issuance in Series</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units in such amounts and in numerous distinct series as we determine. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a><a name="tIBR">&#8203;</a><a name="tLEMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an internet website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of certain information filed by us with the SEC are also available on our website at https://mindmed.co/. The inclusion of our website address is intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained in, or that can be accessed through, our website address is not incorporated by reference into this prospectus and is not part of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference in this prospectus (i)&#160;the documents listed below, (ii)&#160;all documents that we file with the SEC under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration statement of which this prospectus forms a part, and (iii)&#160;and any future filings that we may make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering under this prospectus; provided, however, that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed, including any information that we disclose under Items&#160;2.02 or 7.01 of any Current Report on Form 8-K, in accordance with SEC rules: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024021656/mnmd-20231231.htm">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, filed with the SEC on February&#160;28, 2024</a>, including portions of our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1813814/000110465924052454/tm2412544-1_def14a.htm">Definitive Proxy Statement on Schedule&#160;14A, filed with the SEC on April&#160;26, 2024</a>, that are incorporated by reference into Part&#160;III of such Annual Report on Form 10-K; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024055681/mnmd-20240331.htm">Quarterly Report on Form 10-Q for the quarterly period ended, March&#160;31, 2024, filed with the SEC on May&#160;8, 2024</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K (other than portions thereof furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits accompanying such reports that relate to such items), filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000119312524061361/d682854d8k.htm">March&#160;7, 2024</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000119312524064380/d787577d8k.htm">March&#160;11, 2024,</a> <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024039484/mnmd-20240401.htm">April&#160;1, 2024</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024071953/mnmd-20240610.htm">June 11, 2024</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1813814/000095017024075317/mnmd-20240620.htm">June 20, 2024</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common shares which is contained in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1813814/000110465921053876/tm2112540d1_8a12b.htm">Registration Statement on Form&#160;8-A, filed with the SEC on April&#160;22, 2021</a> under the Exchange Act, as updated by <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1813814/000095017024021656/mnmd-ex4_1.htm">Exhibit&#160;4.1</a> to our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, filed with the SEC on February&#160;28, 2024, including any amendment or report filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may request, orally or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost by contacting: Mind Medicine (MindMed) Inc., Attention: Corporate Secretary, One World Trade Center, Suite 8500, New York, New York 10007. Our phone number is (212) 220-6633. In addition, copies of any or all of the documents incorporated herein by reference may be accessed at our website at https://mindmed.co/. The information contained in, or that can be accessed through, our website address is not incorporated by reference into this prospectus and is not a part of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise specified in a prospectus supplement, certain legal matters relating to the securities will be passed upon for us by Hogan Lovells US LLP with respect to matters of United States law, and Osler, Hoskin &amp; Harcourt LLP, Vancouver, B.C., Canada, with respect to matters of Canadian law. Additional legal matters may be passed upon for us, any selling security holders or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. As appropriate, legal counsel </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:512pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">representing the underwriters, dealers or agents will be named in the accompanying prospectus supplement and may opine to certain legal matters. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Mind Medicine (MindMed) Inc. as of December&#160;31, 2023 and 2022, and for each of the&#160;years in the two year period ended December&#160;31, 2023, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:39.76pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to 8,000,000 Common Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:26pt; text-align:center; width:456pt;">
          <img src="lg_mindmed-4c.jpg" alt="[MISSING IMAGE: lg_mindmed-4c.jpg]" height="53" width="240" >
        </div>
        <div style="margin-top:23.13pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Offered by the Selling Stockholders</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:191.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 191.166666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:22.64pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:18.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 18.8333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:242.05pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">October 17, 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:38.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 38.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>tm2423581d4_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 107</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form&nbsp;424(b)(7)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Form&nbsp;Type)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MindMed (Mind Medicine) Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Table 1: Newly Registered and Carry Forward
Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Type</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Class&nbsp;Title</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Calculation<BR>
or Carry<BR>
Forward Rule</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount Registered<BR>
(1)</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed<BR>
Maximum<BR>
Offering Price<BR>
Per Unit</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum Aggregate<BR>
Offering Price</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Rate</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of<BR>
Registration Fee<BR>
(2)</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Shares, without par value</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000,000</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24(3)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,920,000.00</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.0001531</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,417.95</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Offering Amounts</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,920,000.00</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,417.95</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fees Previously Paid</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Fee Due</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center">-</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,417.95</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Pursuant to Rule&nbsp;416(a)&nbsp;under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), there is also being
registered hereby an indeterminate number of additional common shares, without par value, of the Registrant (the &ldquo;Common Shares&rdquo;)
as may be issued or issuable resulting from share splits, share dividends or similar transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD><FONT>In accordance with Rules&nbsp;456(b)&nbsp;and 457(r)&nbsp;under the Securities Act, the Registrant
initially deferred payment of all of the registration fees for the Registration Statement on Form&nbsp;S-3 (Registration No.&nbsp;333-280548),
filed on June&nbsp;28, 2024, other than in connection with $150,000,000 of Common Shares that may be issued and sold from time to time
under the prospectus supplement included therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Estimated solely for the purpose of calculating the registration fee according to Rule&nbsp;457(c)&nbsp;under the Securities Act based
on the average of the high ($5.44) and low ($5.03) prices of a Common Share as reported on Nasdaq on October 11, 2024,
which is within five business days prior to filing this prospectus supplement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lg_mindmed-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_mindmed-4c.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !&
M  #_X0,Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;7 Z
M0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<" R,RXU("A-86-I;G1O<V@I
M(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C)$,C4P,C8T-S=!-S$Q148Y
M0T4Y.41"1#=&1C8S144V(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C<R
M14%"041#-S=",3$Q148Y0T4Y.41"1#=&1C8S144V(CX@/'AM<$U-.D1E<FEV
M961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z,D0R-3 R-C(W-T$W
M,3%%1CE#13DY1$)$-T9&-C-%138B('-T4F5F.F1O8W5M96YT240](GAM<"YD
M:60Z,D0R-3 R-C,W-T$W,3%%1CE#13DY1$)$-T9&-C-%138B+SX@/"]R9&8Z
M1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME
M="!E;F0](G(B/S[_[@ .061O8F4 9,     !_]L A  $ P,# P,$ P,$!@0#
M! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,$1$1$1$4%!04
M%!04%!04 00%!0@'" \*"@\4#@X.%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !3 7<# 1$  A$! Q$!
M_\0 PP !  (" P$!              <)!0@#! 8! @$!  ,! 0$!
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MQ^^.FHM]44IIWB2H)UG2E22>,I\%)/+G\-N=N-V&^.J.'+B23&8=" $ ( 0
M@! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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M#K)55S%WNBE-41KJ8,,K=2@K#>O6J2E:9)!YJX<R(GGBSBJLY4DR=XJG8@!
M&N^0=ZNQ^.WRXV"IJKC4U5LJ':-]^DI [3J=844+Z:RXG4G4" H"1YCA%R.)
M<:J<;T3IC=^H,JQZTY/:M?NR\T=/<*+JIT.="J;2ZC4GC(Z5"8BK*.UT9V1E
MN#W/[.;9Y&<4R:].>^VM!K6*.G=JA2AP!2>LIL$ E)U:4S5+PXB<T,><U5(Y
M<DB4[->;5D5IH[[8ZMNOM%P:14458PK4VZTX)I4#_P!)1 TTZ,Z.]'@$ ( 0
M @! " -?.Y#N6J=@Z_'Z)C&T7X7QFI>4M=8:3I>64VF0 9=U3ZGJBW8Q_5KQ
MI0XE*A[/8/=Q[>O 1FK]I395FMJ*+R2'S5"5.$'5K+;?/5RTQ'>M>G*E3V+J
MC][N;\8'LH;0,U-8/??F/)>2I_,?[)TNIK]I,OXU,H6K,KE:<@Y4./:7?_;K
M>E^YTF%U-1YVTI:=JJ6N9\NZ6GBI(<0-2M204R41\4D3YB%VQ*WJ%),E&(#H
M0!BLER*T8CC]RR>_U I;-::=RLK7SQTM-)*C(#BI1Y)2.),@.,=1BY.B!!N.
M=Z.R^49!:L:M:KK[SO-93V^C#M$$M]>K=2TC4H.&0U*$S*+4L2:570XWHV'B
MF=B $ ( 0 @! " -'$_6"7 WWW-^8#4O-&EZOO54Y!S1JEY7[,IQJ?HE2M2+
M>;FY*_2LV2M%6\EA#K2VT*5XK4DZ0!S/'T10M)N2H3QU(_Q[-';-;S;VJ U;
MG44X%)64R2H#A()5XB+]S'WNM:$D^+J>LQW-J>_5IMRJ1RFJPDKD3K1)/.9D
MDCGZ(K7<=P5:U1"9NOO5IM9";A6LTRU<4H<6 HCTRYRB"%N4M%4\;2/%Y%:G
M;[D=EOMD#55;VU-^<JVG$:$!AS62LS\$_P#5%^S-6[<HRX/DB&2JTT>M;RC'
M':GRC=UI55!.D(#J>)] ,Y$Q3>/<2KM=#OU(UI4XLJR:EQ2V"Y53+CX4XEEM
MMJ7%:@3Q)X 2!CK'L.]+:CF]=5N-61]4;R5?1<6;"MNG<2I+;Q>40"1('BT
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MF-X[;:H5]:VV^ZAQ**9HA;ZUK!'!"3/F>9X>N.\;%NW9+:OZ$>3E6K4'N?\
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- @! " $ ( 0 @#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tb_candidate-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_candidate-4clr.jpg
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M U)//"\><53\*<Z8;7*P-24^>%X\XJGX4YTPVN5@:DH\\+QYQ5/PISIAM<K
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MX4YTPVF5@=<N#EY7DA!J3<=3QV8?UMSH_&,9GMLN+9F([%B^:O%4_P#JD_\
MO+O^\.WM_P!<?1F_F\H]#  8@&(!B  )  $  "=@" $D @  2  ( 2 @!(
M@!("    " 2(((42  (  '2W_:7OS4CS6?MN;GD[QZ6$ )   !   D00*
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M"2V$0X>TMBV;HC%NZ:VQ+YC'O<    '3(X6/^9_[)CAF?=;]?\-QR=P[L
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MM!'D;Q(L"/\ F_#@/-G=%]_1%(QENV.%7Q"ZI2WG5K3D<6XM2T<&52E&9E^
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MEI+ E.EA@9D1= )R;)BDQR74FM72G5#49%8J=P)NBHE7*S'.#5:@;V9Z1%/
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M_E'+.^R?HU;S>ZI_]4J']Y=_WACV_P"N/HM_-Y1Z&$ ) 0 D   $
M  "0#XP#:   " $_" <(      @  3Q@ " $@( =+?\ :7OS4CS6?MN;GD[^
M$>E@V (   !.P   $     ) 0   #H_^N_[K_6/+_P"[^'3L>CX!ZG-   $
M&          ) 0  )(!T.?VIC\Q?\I#SW?LCZ2W_ .+O'H8    0  ) 0
M   &("0#@ 0 Z9'"Q_S/_9,<,S[K?K_AJ.3N'=D 3P ( 3Q (       !(
M@   $@.ACY<C\\O]TAY\O[[OX;GD[]@]#" $\0!QD9<1D?XCQ$5NVINIU9U5
MFT*?7H,.(];]*8H<0H27")<>,I2DK7O5K/.><\<N!? .65E196G;+I=?7DDM
M4*V5D6Y87(XGDJV*JY6X<G!SE#LAY68T.GFRY,?R4D?PAI1U3=C"S?6*+$C^
MUI?R+GN&OSJ+1*C3KG;CHJEMS8[C]+-<0L&W$H6X:LV.T\588_@'#:V],16>
M':=?%PJWM67A6KVHU[U"V+><DT2"Y3(M,5&>7!-APU'B:''5*2:<W4Y%$+'M
M8BV;:SQ)NB9JXO\ M9ZFO:AMZA%'IJ'&Z>=&.A$TM5-7 4K.;2DJ6:]J^JQ)
M>./P; VMG1TG7Q:3JMJY6=6IE.D52DTNB0Z4RN/"I]&8Y,PE#ADI1GB:C,S,
MNCLXAURLJ,NO&9JS==7DW.RO:JOVRK8IMM,T>B59=#2ZB@5>HQ3<G04O_+W*
MTJ22<?BV\8Y7^UMNNF:SQ:MOI%%-5JL5&X:Q/K]7>.35JI(<F3I!X$;C[RLR
MU'A@6TS'JMB(BD.<S5X!ID  '3+_ +,O_P!7_>(>?W'ZY_C^[IE\W>?"8]$L
M2@$         $@(Q 3P (     <'O^$?X/Y1RS?LGZ-6\WUQ+]@;561,DR4W
M+;Q(?=6ZDC7-Q(EGB1'_ %<?-RO>6VVQ%)X/3.75U?=_ZKG_ /DMO=?-\6'7
M?V82SI0?=_ZK\Y+>Z^=XL&_LPDTH/N_]5^<EO=?-\6#?V82:4)^[_P!5^<EO
M=?-\6#?V82:4(^[_ -5^<EO=?.\6#?V82:4'W?\ JOSDM[KYOBP;^S"32@^[
M_P!5^<EO=?.\6#?V82:4'W?^J_.2WNOG>+!O[,)-*#[O_5?G);W7SO%@W]F$
MFE!]W_JOSEM[KYOBP;^S"32A/W?^J_.6WNOF^+!O[,)-*#[O_5?G+;W7S?%@
MW]F$FE"/N_\ 5?G);W7SO%@W]F$FE!]W_JOSDM[KYOBP;^S"32A/W?\ JOSE
MM[KYOBP;^S"32@^[_P!5^<MO=?-\6#?V82:4'W?^J_.6WNOF^+!O[,)-*$?=
M_P"J_.2WNOF^+!O[,)-*#[O_ %7YR6]U\WQ8-_9A)I0?=_ZK\Y+>Z^=XL&_L
MPDTH/N_]5^<EO=?.\6#?V82:4'W?^J_.6WNOG>+!O[,)-*#[O_5?G);W7SO%
M@W]F$FE"?N_]5^<MO=?-\6#?V82:4(^[_P!5^<MO=?-\6#?V82:4'W?^J_.2
MWNOF^+!O[,)-*#[O_5?G);W7SO%@W]F$FE!]W_JOSDM[KYWBP;^S"32@^[_U
M7YRV]U\[Q8-_9A)I0?=_ZK\Y+>Z^;XL&_LPDTH/N_P#5?G);W7S?%@W]F$FE
M!]W_ *K\Y;>Z^;XL&_LPDTH>&J^P9K+!80Y J=#J;JEY5,LO/MJ2G SS&;[3
M98<6P\1F??V]D&DQ/N/Z]%_[BE>%I[(9^0_%-)[J1[!>L\MR0]4*E0Z7\DDH
M?>><-6'&1L-N?Z1BSWL1=-TQS:TV6^[_ -5^<EO=?.\6'??V82FE!]W_ *K\
MY;>Z^=XL&_LPDTH/N_\ 5?G);W7SO%@W]F$FE!]W_JOSDM[KYWBP;^S"32@^
M[_U7YRV]U\[Q8-_9A)I0?=_ZK\Y+>Z^=XL&_LPDTH/N_]5^<EO=?.\6#?V82
M:4'W?^J_.2WNOG>+!O[,)-*#[O\ U7YR6]U\[Q8-_9A)I0?=_P"J_.2WNOG>
M+!O[,)-*#[O_ %7YR6]U\WQ8-_9A)I0?=_ZK\Y+>Z^=XL&_LPDTH/N_]5^<E
MO=?.\6#?V82:4'W?^J_.2WNOG>+!O[,)-*#[O_5?G+;W7S?%@W]F$FE ?L :
MK%PW+;Q?^O-\6#?V82:4-3+V-=1%:C*L(J_1/*J*8FIF_FE;@VEN*022/<YL
MV*<?DX8<8X[RW4ZJ3R:T^#;?N_\ 5?G+;W7S?%AVW]F$LZ4(^[_U7YRV]U\W
MQ8-_9A)I0?=_ZK\Y;>Z^;XL&_LPDTH/N_P#5?G);W7SO%@W]F$FE!]W_ *K\
MY+>Z^=XL&_LPDTH/N_\ 5?G+;W7S?%@W]F$FE"?N_P#5?G+;W7S?%@W]F$FE
M!]W_ *K\Y;>Z^;XL&_LPDTH1]W_JOSDM[KYWBP;^S"32@^[_ -5^<EO=?.\6
M#?V82:4'W?\ JOSDM[KYWBP;^S"32@^[_P!5^<EO=?.\6#?V82:4)^[_ -5^
M<MO=?-\6#?V82:4'W?\ JOSEM[KYOBP;^S"32A'W?^J_.2WNOG>+!O[,)-*#
MW -5BX;EMWKYOBP;^S"32AK,_P!BW4:'?-'LQRX*&=1J4&5/9>)4O<$W&6A*
MDJ,V25F/,6&"1SGWMLWQ-)Y+IMF]P'57'#SEMW'H9YN/S8=-_9A*:4)^[_U7
MYRV]U\WQ8-_9A)I0C[O_ %7YRV]U\WQ8-_9A)I0?=_ZK\Y+>Z^=XL&_LPDTH
M/N_]5^<EO=?.\6#?V82:4'W?^J_.2WNOG>+!O[,)-*$_=_ZK\Y;>Z^;XL&_L
MPDTH1]W_ *K\Y;>Z^;XL&_LPDTH/N_\ 5?G);W7S?%@W]F$FE!]W_JOSEM[K
MYWBP;^S"32@^[_U7YRV]U\[Q8-_9A)I0?=_ZK\Y+>Z^=XL&_LPDTH/N_]5^<
MEO=?.\6#?V82:4)^[_U7YRV]U\WQ8-_9A)I0C[O_ %7YR6]U\[Q8-_9A)I0?
M=_ZK\Y;>Z^=XL&_LPDTH:W<GL5ZCT&LVU19=P4-<BX9;L6(XVJ6;:%LL*=,W
M#4P1D1D6&PCVCE?[VV9B:3P72;)[@&JQX_\ F6W>OF^+#KO[,)32@^[_ -5^
M<EO=?-\6#?V82:4'W?\ JOSEM[KYWBP;^S"32@^[_P!5^<EO=?.\6#?V82:4
M'W?^J_.2WNOG>+!O[,)-*#[O_5?G);W7SO%@W]F$FE!]W_JOSDM[KYWBP;^S
M"32@^[_U7YR6]U\WQ8-_9A)I0?=_ZK\Y+>Z^;XL&_LPDTH/N_P#5?G+;W7S?
M%@W]F$FE!]W_ *K\Y+>Z^=XL&_LPDTH/N_\ 5?G);W7SO%@W]F$FE!]W_JOS
MDM[KYWBP;^S"32@^[_U7YR6]U\[Q8-_9A)I0?=_ZK\Y;>Z^;XL&_LPDTH/N_
M]5^<MO=?.\6#?V82:4'W?^JW'<MO=?-\6#?V82:4-9MWV+=1Z[<5TV[%K]#1
M,MR1&9F..*EDTM4IG>IW9I8,S(BV'F(MHY6^]MBZ9I/%=/@V;[O_ %7YRV]U
M\[Q8==_9A*:4'W?^J_.2WNOF^+!O[,)-*#[O_5?G);W7SO%@W]F$FE!]W_JO
MSDM[KYOBP;^S"32@^[_U7YR6]U\WQ8-_9A)I0?=_ZK\Y+>Z^=XL&_LPDTH/N
M_P#5?G);W7SO%@W]F$FE!]W_ *K\Y;>Z^=XL&_LPDTH/N_\ 5?G+;W7S?%@W
M]F$FE!]W_JOSDM[KYWBP;^S"32@^[_U7YR6]U\[Q8-_9A)I0?=_ZK\Y+>Z^;
MXL&_LPDTH/N_]5^<EO=?.\6#?V82:4'W?^J_.2WNOG>+!O[,)-*#[O\ U7YR
M6]U\[Q8-_9A)I0U34GV-=0]/++J5X5>O4253Z<J,3K$14M3RN4RFHZ<N=A"=
MBG",\5< Y9OO+;K9BDM1ET;8?_\ 7_JN9F97);V'Y\[Q8==_9A+.E"/N_P#5
M?G);W7SO%@W]F$FE!]W_ *K\Y+>Z^=XL&_LPDTH/N_\ 5?G);W7S?%@W]F$F
ME!]W_JOSDM[KYWBP;^S"32@^[_U7YRV]U\WQ8-_9A)I0?=_ZK\Y+>Z^=XL&_
MLPDTH/N_]5^<EO=?.\6#?V82:4'W?^J_.2WNOG>+!O[,)-*#[O\ U7YRV]U\
MWQ8-_9A)I0?=_P"J_.6WNOF^+!O[,)-*$_=_ZK\Y;>Z^;XL&_LPDTH1]W_JO
MSDM[KYWBP;^S"32@^[_U7YR6]U\[Q8-_9A)I0?=_ZK\Y;>Z^=XL&_LPDTH/N
M_P#5?CN6WNOF^+!O[,)-*'%?_P#7]JLM)I*YK=Q/#^?-Z/\ =AB_WMMULQ25
MC*A^BN5/0'R'9)%AL
M  1D3T/@ 2       !@           "#(C+ ^ !2K?\ FB?_ ,+,_.' %U@
M                  @R(^$@%27"1>\+9A?_ / JO].R MO*GH )
M           !4^JO\>Z5_M:=\Q6"K621%B9%Q@CD                   "
M#21GB9;0%2Z8?6IJ[^T*5\R,!;8                   *8]JHB+0:Z\/RZ
M5^]8@"YP    #                $92PPPV )
M                                               4JW_FBD?X69^<
M. +J                     5'<7^8:S/V!5?Z9D!;@
M    "I]5?X^TK_:TWYBL%6N7'\8(D                    !4FF'UJ:N_M
M"E?,C 6V                   "F?:K^H:Z_P ^E_O6( N8
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M\/\ X/ .NTS<$F^(BJ\XLEJ9&9EL'F8D(2ZTK RQ0LB4D\#^ QY9BC;M$
M                      !!G@6)\! ()Q)\'_;$!&\+'# !S+:    9X;0'
M G"/@_[8 .8#BI9) ,Y<>P 2K-Q&7Q@.1G@6(",WP?& C,7^L!..S$ (\>
M4HDEB>PNB I5K;[44C_"S/SAP!=8                   (4HDX?" J.X3)
M7M"V89<'D"J_T[("W"41F D                   %3ZJ_Q[I7^UIWS%8*M
M5"B5CAT3!',  ,0                '#.6;+Q@*GTQ^M35W^_TKYD8"VP
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MA$U[6NU]/MD24)2DB2DBP)*=A$1<18#P-N0
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M,CW%N;'#FN<<7I                  !3/M5_4-=?Y]+_>L0!<P
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MAIIC]0-UW!<5!I42-WFR$?4EM).(SJ3-O3V+1M""P21?RC Y
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MM2E*._*]B9GA(218\1;I&PA]O(_7#\S[K]MW]=C5L1V>5&T     ^(!   D
M^(!.P $$;!42"F( ( H  "-H  @!(!B8"1! H%P )P 08" '(!!\ " $D &
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M0?*&I/\ 'E?_ +P7]$@?;R/UP_,>Z_;=_78U4=GF3\8"    2  ) 1\8!C@
MG$!& " '( $$$* !\ " '( (   $<8!\0"1  !0     /B 1B 8 &!@)$
M08H$ D01\8HD0-@H !@(X@ ^$  -H"U] OXDJW]Q1_3$/%[O[8^KZG_SOON^
MCZ!'RWW                   4S[5?U#77^?2_WK$ 7,
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MNI(3ESHE?HR:Q2K,193->8E%B.6;=2D?C#417Q7>E)&1&9;1Y'1R(B+@X^$
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M=3T1X<J(LC2MLWRWZ#41]$B'SO=9D32(?9]AE76UNF*57L1XF/ ^LD
M            4S[5GU#77^?2OWK$"1<P                       .MQAM
MU*D.%F0LC):%;241E@9&7&6'$ AN.TRVAEE)-,MI)#;:")*4I26!$1%L(BZ
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M:CQ,^B9F+,S/&4B*,@18%@(H @RQ(!2K6SVHI!?_ +69+_\ V' 5=8(8
M              #B:<3QQ,@%2W"6'M#69AL_\OU4MG0W[(*MLBP/A!$@
M               J?57^/M*S+895:=@?&1\A6"K626!F8(Y
M       @RVX_Z %2Z8[=5-7>CR^E?Z(1@JVB+ $2                  *9
M]JOZAKK_ #Z5^]8@"Y@
M                                                  4HW_FBD?X6
M9^<. +K                     5'<7^8:S/V!5?Z9D!;@
M       "I]5?X^TK_:TWYBL%6N7'\8(D                    !4FF/UJ:
MN_W^E?,C 6V                   "F?:K^H:Z_SZ7^]8@"Y@
M
M                     4JW_FBD?X69^<. +J                     5
M'<7^8:S/V!5?Z9D!;@                    "I]5?X^TK_ &M.^8K!5KEQ
M_&")                     5)IA]:FKO[0I7S(P%M@
M   IGVJ_J&NO\^E?O6( N8
M                                                     %*M_P":
M*1_A9GYPX NH                    !4EQ?YAK-_8%5_IF0%M\8
M             "I]5?X^TK_:T[YBL%6N7'\8(D                   $&
MJ73#ZU-7?VA2OF1@JVP0                  %,^U7]0UU_GTO]ZQ %S
M
M                             I5O_-%(_P +-?.' %U
M        *DN+_,-9G[ JO],R MOC                     5/JK_'VE?[6
MG?,5@JURX_C!$@                    *DTP^M35W]H4KYD8"VP
M            4S[5?U#77^?2OWK$$%S"@
M
M   *5;_S12/\+,_.' %U                     *DN'_,-9O[ JO\ 3,@+
M;XP                    %3ZJ_Q]I7^UIWS%8*M<N/XP1(
M       (,!4NF/UJ:N_W^E?,C 6V                   "F?:K^H:Z_P ^
ME_O6( N8
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MZ_SZ7^]8@"Y@
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MQ %S
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M#$A1N398$".9F1<(#Y0U)_CROG_]R7]$@?;R/UP_,>Z_;=_78U;XQV>9("
M ,!   Y (XP$@(,! "<0$B *( " 2  (X #A 20@& C:*) <0$@)(!!@( 3B
M 'P@)$$;!0 2((V]$42 C$!(!B C80!^,!( ( H@P$ )X0$B *+6T#_B2K?W
M%'],0\7O/MCZOJ?_ #OON^CZ!Q'RWW                   4S[5GU#77^?
M2OWK$"2%S
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M8 0"0$& ; $B  @Q0(!(@C8*'#P@   8@&(" $\((@% $E@ ?& ; #8 <8"
M$E@ '@ @!(  G8 C8 8@!F @  -GQ=$P%NZ 1W'*Q6YR3(V68[<9PBX4N+5O
M"(_C26(\'O+N$0^M_P#.MGJF>Q?1<)CYK[3D                  *9]JSZ
MAKK_ #Z5^]8@20N8
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MBD+@$4                  %,^U9]0MU?GTO][1 5<P(
M
M   "#2E7"6( 1$18%L(!(   (RIZ "2(B+ @ !!D1E@8"E6_\T4C_"S/SAP!
M=8                   (-*3,C,MI *DN$B+VA;,(BV%0*K_3,@+;RECCQ@
M)                   !4^JO\?:5_M:=\Q6"K6218F?&9@CD
M        ".,!4NF/UJ:N_P!_I7S(P%M@                   IGVJ_J%NO
M\^E_O6( N8
M                                         %*M_P":*1_A9GYPX NH
M                    !4EQ?YAK,_8%5_IF0%M\8
M "I]5?X^TK_:TWYBL%6N7'\8(D                    !4FF/UJ:N_W^E?
M,C 6V                   "F?:K^H:Z_SZ5^]8@"Y@
M
M               4JW_FBD?X69^<. +J                     5)<7^8:
MS/V!5?Z9D06UQBB0                   5/JK_ !]I7^UIWS%8*M<N/XP1
M(                   !@*DTQ^M35W^_P!*^9& ML
M %,^U7]0UU_GTK]ZQ %S
M                                                    I1O_ #12
M/\+,_.' 5=8(                    J2X?\PUF_L"J_P!,R MOC
M              5/JK_'VE?[6G?,5@JURX_C!$@                   &
MJ33'ZU-7?[_2OF1@+;                   !3/M5_4-=?Y]+_>L0!<P
M
M                            *4;_ ,T4C_"S/SAP%76"
M        *DN+_,-9G[ JO],R(JV^,5                    %3ZJ?Q]I7^
MUIWS%8*M<N/XP1(                   !@*DTQ^M35W^_TKYD8"VP
M              4S[5?U#77^?2_WK$ 7,
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MCY1] <G=S                   !!@*ETQ^M35W^_TKYD8"VP
M         4S[5?U#77^?2_WK$ 7,
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MT^9H/ C,LQ8'@/-[J/\ CE[O8S_S1])?6Q$1&9CX[]$Y
M    @!4NF'UJ:N_M"E?,C 6V                   "F?:K^H:Z_P ^E_O6
M( N8
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MCVO_ -Y+^B0/MY'ZX?F/=?MN^O\ AJWQ#L\R3 0  ) !!&(H'L " .$ X $
M "0#$!)  "-H  @!("0$&  & !@ D X0$8 & !B D!&&)@-DT^_C2C_\XAYO
M<_KE[?8_NC^7UI@/COT8                     J33#ZU-7?VA2OF1@+;
M                  !3/M6?4+=?Y]+_ 'K$ 7,
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M#L\R0$8 )   !Q 20"0$ !@( 3@   !C@   "0$ ! ) 1P@& "<0 ! "0
M1@ D!!@-DT__ (TH_P#SB'F]S^N7M]E^Z/Y?69'B> ^._1I
M      ! "I=,/K4U=_:%*^9& ML                   %,^U9]0MU?GTO]
M[1 5<P(
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M;?I];%1M6C28U4?*75:A4)E2F/HV)S3'U.D@O@0DR3^ <LR^+IX+;%&X#FT
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MF1@+;                   !3/M6?4+=7Y]+_>T0%7,"
M
M                I1O_ #12/\+,_.'!!=8H                    J.XO
M\PUF?L"J_P!,R MSC                     5/JI_'VE?[6G?,5@JURX_C
M!$@                    *DTP^M35W]H4KYD8"VP
M 4S[5?U#77^?2OWK$$%S"@
M                                                    *4;_ ,T4
MC_"S/SAP%76"                    *DN'_,-9O[ JO],R ML
M           !4^JO\?:5_M:;\Q6"K7+C^,$2                     J33
M#ZU-7?VA2OF1@+;                   !3/M5_4-=?Y]+_ 'K$ 7,
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MSF19E*WFQ)<9B"WC09F9YC(5',N
M                                  0HL2PQP^(!2K>/O1/EC_\ BS/S
MAP076*                   XJ29\!X?$ J6X<2]H6S"(SP\@57^F9 6W@?
M1 2                   "I]5?X^TKXO_%IW!_<5@JUDD>)GB>'0!'(
M               '$R,SQQ_  J;3''UJ:N_M"E?,C 6V
M   "F/:J(RT%NO$\>KI7[VB +G                    ,L2P <<NW'$P'(
M
M        !2C?^:*1_A9GYPX NL                    !4EQ?YAK-_8%5_
MIF0%M@                    *GU5_C[2O]K3?F*P5:Y<?Q@B0
M          0 J73#ZU-7?VA2OF1@+;                   !3/M5_4-=?Y
M]+_>L0!<P                       (S)Z(!F3PX[ #,GAQV &8NB 8ET0
M#,GHEL ,2Z(!B7#B 8D>S$!(
M                  &9%P@*4;_S12/\+,_.' %U&9%PF D
M     09D1X&>T!4MPF1^T+9AEP>;]4_IF1%6UB1\8J)         ,2
M    %3ZJ_P ?:5_M:;\Q6"K7+C^,$2                   "# 5+IA]:FK
MO[0I7S(P%M@                   IGVJ_J%NO\^E_O6( N8
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MTP^M35W]H4KYD8"VP                   4S[5GU"W7^?2_P!ZQ!%7,*@
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MM-^8K!5KEQ_&")                    ,!4FF/UJ:N_P!_I7S(P%M@
M               IGVJ_J&NO\^E_O6( N8                       '@K
M-(IU?I4VB5=@I-+J#*XLV.:E()QEU)I6G%!I46)'Q'B+$S$U@F*O-;EM42T:
M%"MFW8B85!I[6XB0R6XYD;VGAF<4I1[3XU"W73=-9(BC4&M"M)V+?AVJU;B$
MT"GU'RW#A<IEF3=0,R4;V8WLY[2+J35E^ ==>^M:\6>F&V75:EOWO;\RU;HA
ME4*#4"0F9#4XXT2R;6EQ/5M*0LL%)(]BARMNFV:PU1X:SIQ8]PVZY:M8HD>5
M0W8S4);"B4EPX["4H;1OD*)WJ4I(B//C\(U&9=$UB>*=,/'<.D>G%UVO"LRO
MV]'F6W3B04"$9N-FQNRP(VW6UI<2>!;3)>)\>(MN;=;-8GBG3#'RM"-)9ED1
M].7K98*S(TDIS=+:>D,D<HDJ3O5NMNI=6K!1D9K6>/X"%C/OZNJO%:.^P=%-
M,=,)TNI6+0BI,V>RF-*=*3+D9V4JSDG"0\X1;?R2(,S.OO\ NDB*-\P)/ .*
MF.WA_  Y                                 ,2W;5#:N)Z[$1"\X7XI
M0')QJ6I?)4K)S=I(U&E*<Q$H\I%B?"-=4TIV)2*U:Y5-)K JT.HP9U'4J/5*
MH=>F*;DRFG?*:D);-]MQMU*VS-*2(R;4E/P#<9MT=O91.F)=/J:TV*WX5L,T
M/<46G2EU&"VQ*E-.M2G3S.+2^AXG>K,^J3GP/C(-:^M:G1$<'.IZ0:>UN-(A
MSJ2X4>7/E5:4EB;-BF[-G8%(6HV'T&:7,"Q1CD^ 6,ZZ.TFV&3+3NRV6I[;5
M);;:J4./3)J$+=2ER'#(R9;P)>"23F/:G SXS,9U+L3IAZH5J6[ K#%>B04M
M5B/3FZ(Q)SN&::<TYO4,Y34:3(E;<V&;X1)OF8IWU6D,)<VD.G5WUKS@N"BE
M)JJDH;D.H?DQT2$-%@A,AMEU"'B26PMZE6S9P#=F=?;%(E)MB6N570:U+BO>
MJ7+<L1N32)$&!3Z93XCTJ";+<$EDI#A1G&DK:41I(D'BG N ;C/NBV(CFG1$
MS66R5S2;3VXY4&=4J*27J:RB)$.&_(@IY,U\AA:8KC25MIPZE"R,ASMS;[>4
MM=,(K>EE@W%7F;GJM(-5;:)I/*F9,J(3J8YXL[]##J$/9/YN\2K MG %N;=;
M%(DFV)1.TDT_J<BOR9]%-Q5T)0FOMIDRFV91MK0X2S:0Z2$KS-(Q6@B4>&TP
MC-NBG'D4AZ+QTQL>_)$:5=E*Y<_%0;+;Q/R(JE,J/$VG#CN-[QLSVY%XIQXA
M+,VZSE*3;$\TQ].+(IU-GTR/24,4VITY%#G-&\]E<IR&U,I8-1N8I+(LTDHC
M)6WAQ"<RZ9K7MJ1;$,E3[,MBG2:5/A4]+4JBP2I5,<)QU6YA)2E!-$2EF2B(
MDD6*L3^$2;YF)C%:16K/D1%P#"AD1\(#Y1U)_CRO_P!Y+^B0/MY'ZX?F/=?M
MN_KL:M@.SS)P(   $  !L -H  <("<  !&/$ 8F D@$& $ D0!1&)@'" @
M  !R ?4FD_U>4+_E.?TS@^-[C]DOTOL_TVMS'G>L      %3ZJ_Q]I7^UIWS
M%8*M<N/XP1(                    "I-,/K4U=_:%*^9& ML
M         %,^U7]0UU_GTO\ >L0!<P                       ->O6YX]
MG6M5[EDY5(IT=3C:%XD2WU8(9;,RX,[BDHQ^$!0]W:_:F6RQ6JJ[2;<CTZT8
M$"5<L";*E(J*YLUAM]<2&2"-M;B2<)!9CVJZ) +9H>H,BO7[4[<BQF6*#0J5
M"DUJ1(4I$MBJ50DOQV"(SRJ0;!J4I7$HL 'I?O>5#U'A6;(88\DU*ER*G#G)
M4><E0UH2Z2_YI)_2%E,!KNINL:]/KPT\H2(;,VCWA-D0JI.)2LT)M"4;IXLO
M4Y,RE9S5P$0#6J_[1CL6][]MJ@4MF;2K'M:H5M=2<6LN4UF ZEGD:,NS(E2L
MCA_*)7  R=G:IZ@L5&WH&J%(I,5F[:>[4J).H+TAQEI3#+<A3$DI1)42S0YU
M)H(T[#V@,!1O:CCNZ67%>U<I.XN2B5-ZD1J''SJ*6^X9K@DVI7$ZT:%*5P$>
M/Q /=<6OE>H5D6+5RHD:5=ES-Q)U9IC;JR9I].6I/*9)F>"S2C'(DS_G8 +$
M*^9*=1*7:.X972*U2G:I3IJ#5OL8QMYR61]223)U)IP ;P
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M !. ", $X (P , #  ,!(#ZDTF^KRA?\IS^F<'QO<?LE^E]G^FWZ-S'G>L
M    %3ZJ_P ?:5_M:;\Q6"K7+C^,$2                     J33'ZU-7?
M[_2OF1@+;                   !3/M5_4-=?Y]+_>L0!<P
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M<@C-27YR$X3%-FHB,T8(:P5QXGT %T
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M=_O]*^9& ML                   %,^U7]0UU_GTO]ZQ %S
M             ZU)Q5C@?QD X*0:B(C+';MQ+H .656!X\7 ()(E8D9XGT2,
M4=@    #BLC,MG" XI)6PSQ/;P'_ *@'8
M                          XJ(S+ N'BQ 4JR1E[4+^/#YK,X]O<!5V @
M          (V@&T!(    #@O-B6'X3 5+7\2]H2S,=BO-^JELZ!OL@JV^JQ!
M'(        !QZH!*> MF'P )       !4^JO\?:5_M:;\Q6"K7+C^,$2
M               " %2Z8_6IJ[_?Z5\R,!;8                   *9]JO
MZAKK_/I7[UB +F
M                                             !2K?^:*1_A9KYPX
M NH                    !4=Q?YAK,_8%5_IF0%N
M   *GU5_C[2O]K3?F*P5:Y<?Q@B0                    %2:8?6IJ[^T*
M5\R,!;8                   *9]JOZAKK_ #Z7^]8@"Y@
M
M                !Q7L+I<("LF[1KA:Z.7N;23M]RA-TXG\W5E(0ZI9D:?B
M40*L\$                  !UK/!1=$O^W  K^JVK6)FKUMW<RA!46ETB="
MEK4OJR?D.M*024X;2,DGM 6"7"6W$!S                   !H%^VM5Z]=
MEB56GI0<*@SI4JI*6K*:6G8JFDFDL#Q/,8*WQ!X[01S
M  !U+,R4>&W@V<8#0['M6L42^]0:]/0A-.N&5 ?IBD*S*4B/%-M>8L-ADK8
ML$                   %::[6A6[^TJKUJ6^EMRLU!< XR'E;MLRC3X\A>*
MMO\ ,;5AL!5ED9&6)< (
M                                                 (,B/A+$ )))
MX" 2                   "#(CX0# @# B 2                   "#21
MGB9;0 DDG@ 2                   "#21[3 "(BX $@
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M2TDUN&E*$[5*4>!$7PF8#FA1J3B98 .0
M
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M 7VUC@9F>.)\((Y@
M
M                   J&TM0&*QJ1<U&8NEJI4"DYHCT*033;[=55((MW'W:
M$FIEI/Z)9K,SSX -[O:8_3K4JLZ+4VJ))8CJ6W59"-XS'41E@MQ."L4EQ[ *
MJ(MS6VZTOQ9%0G4]^@,TLWY;TP]\Y/?8ENHD2H$B(AME3#31(6M*BS(+8>)X
M@J+@U\N&>4QJWY5,I\:-6$0X9K2^<^JPRJ+3)/P2,S;-!-F:7S6GHY<-@@]$
M[7R\XK]:BPZ?2$G2:<[)/RJX['>4IMTOZV>"DI5%-)F24H+.I6PC%1M5S:IU
MZ%;EK5^@-QICU;H]3J2FG6G68SK\.*VZUU*CWB&S4H]AJS8 KKJVKETT?3BI
M7%+@T]-PT^KOT-V492"H[:F'DM<H<+-O2;/' BS8XX C6ZQ[05X4R+4,U,I,
M:1"I;52*8\I]V#OI$AB.<8UMJ+,IA+AO.Y3^2I!<..)1>L]W,/O37)5)0UR&
M.PU.4E_S=W[E5D1CF$HCWV0VVR3AGX2!&2:UFO5Z'(J$J)1:13<*7'8J$\I1
MQV94^,<EQ^2:%;(YFG<LEB2LZT8GAB"L#;.NU\U*GM5BJ^3%JDSF=U1(#3Z9
MC<)QN46^6;IJ2;*CCYR47592/:",A%UPOV339M0B1[?J,>C-.SYU2AE,.'.B
M-,H>R0L59B=(U[I1N=3F2?$"LYJKK'7+&J<2+2VJ6E"D0'7(-4*0<V:F=*:8
M5R+<J2@]R2S4LU\9"#!7#K5?=)I=1B3TT.EU94--0@U=Q,KD+3,EN4IJ,LE*
M-1RS..1H-/4'T!1VEJE=2+8HEU-S8;++5,HD.7*JJ5IA%6JM&;DR)$@V<JC:
M0VLDX(,L',2!&Q6YJA>58I%V5^;2Z?'IMOT)FIQ&D;[?R9SD-4I6.96!,&:3
M2DOE8<8*U.+KC>#K"JL\W J+,&"N?FH:7C@N*D;I!1WM]F7O8F8W7\BL,AEA
M@8#G1=:+UK%:J1)BVW4X-L,1IDZKP$2S3)B2G";>3!6M9FE>W8:^IZ.(([G=
M9]0&(=#FSH%,W]<A/U>G1XB7R03#4"0\3,DW5&><WFT;6S(LN(#HKFO%[4.A
M[Z='H,6M19CD26J0F9R.;NDPE;F$1+)>^PEG_P 0\.IQ!6QZMZH71:5PRK9H
M#E-:6[;D^K4Y3R'I$[E\$E.&2D-JRH92V1*Q6GJSQ(@1KLGV@+FAU"#&;11)
M[3YN1I$>.F64HC;A.R?*19E92@K4@E)Q+/N\=N.T%>2E>T5>,N;&@%#H4TRK
M,JG.SXJY#$.H18S49S^H..K/!U._4:S<Q3@18$ ^CX\F/,8;DQG4O1W4DIEU
M)XI4D^ R,MFT$<\O588X&>/!M_\ TP 2:5%@?'T>, /-\HCX> _A/@V KEQ8
M%P?C,$"(RX?B+X,0#*K###@ 0:5[<"^/9M^#X $DE>.TMGQ8@&4S3M(RXL/@
M_ "AI5A@2?\ MT=O "!)4DRV8]'_ -'Q@H:5= \<>+I@B,BN(L-N)_\ 8P$J
M2>WJ<2Z #K?C-26C9D,I=946*VW$DM)\>!D?#@ [,%Y=I=6>P^@ @DKPZI.)
MEP<7XP$D2\<<-G%\!=#H !H5@>''P=+;L 0258$679Q8<7P'B [&R-)8'L^
M!S
M
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M*(\Y$=0R^TE6)F2T*66Q6&);2V +%Z'_ &V@)
M
M
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M 69L
M
9                              '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>bc_pipeline-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_pipeline-4c.jpg
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M%!04%!04%/_  !$( =T#M@,!$0 "$0$#$0'_Q #-  $  @,! 0$
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M   2Z;^>M?\ 5_VF/-Q/^.?X[WHT>U%/A'I<:NV7P&0  /\ D"@#Y=3WBR<
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MXXR)SZGDMJ<LOJ2D\EY5A7E>^/NF,4Z=-/9%C=6I,M!85MMF4^$QT<[0B(N
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MS8^D=N4N 10  +2ML[I]P    !\):#4:241J+A*W**EL/HB@
M
M
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MO&
M
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M(K+QY1*:*:>R+%U-:O4_5,S8UPVY
M
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M2J_33.2R32#*._Y*B>;<M/R^"Q!D)/&U;H:C]JTXM_-5M^'D_0P\#[
M                                                     .>[DONY
M@_I]9_6\L%ET($                <YW[?==6/\^F?K*,"PZ,"
M        "@5?[Y\*?P]7OG=* 7\                  <TWQ?N#_&5'_+ K
MI8(                JV\O[N,8?0E2^:. )>"/V+PY]%POFZ &^
M                                                         ?#,
MBLM.RW(5O? ?0           <]W)?=S!_3ZS^MY8++H0(
M YUOT2I6["KI25JCD4PB(N$S.IQ06'100                 4*K(4>^7"B
MR+R2P]7[3_\ [=)\8"^@                 #FN^$C,L!&19"QC1S,^]E=(
M%=*!                %6WE_=QC#Z$J7S1P!+P1^Q>'/HN%\W0 WP
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MD<\XC#"6:>M41>81(//O+N,_&+0A-TB.^%.G3;;$3W?_ $FJ;%DQ@N=6-WV
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M_'3\(?B'$?Y:OC/XH [/.
M                 M6[;]O,/_IC?_$?/_<?^M7\'U?VG_MZ?_*'[$'YJ_8@
M               %6WE_=QC#Z$J7S1P!+P1^Q>'/HN%\W0 WP
M        *_BW%",+PX*T153ZG59T>ETN A6;-Z1)49G:NQ5U+;27'EJLR(0?
M= ></XUH>(8$:HQWM7CSYTVF4PI*D(5+=I[K[2S9*\=XE%'<<1W;A6V$ ]1<
M<X.G2FH4.N0GY+T=<QI#;R%$<9HU$IRTCL))7%9;>X?> 1T[R, KIQ59.(Z>
M=..1J27]818J4:;Y-)*VU2U),EI216J3Y16EE ).\+"+7+#$2L0I=4HL>1)F
M4]$IE#J4Q$VN7C6HDI)*C)"UJ.ZA611D8"#4-YM!A5JD87;<:DXHJ,IN+-H[
M4EDWX*3C.2WG7K#,C2RAOR[O]I/<40#=4O&6%*W!G5*CUB)/@TV\<Y^,ZEU+
M1(2:S-5TSR&DKR3X%%E*T@%?PIO1@XFJ%*ILBCU"BO5^FG6Z N>3!MS(2<V:
MKJF'7;CJ$O-J6TY=41*(RMRV%;%6\G!*,0US##U798JN&X;51K27CS;4>.]:
M9*6XJQ%J2))J*W(2D]\$9"WCX"5 8J:<24XX,I\X<9XI+?QDI))4IE)6VFZD
ME%>;LO%W2 0Z1O8W>UN W4H5>C)BO5!^C1C>7F5OSH[F;4VRA=BG+<BDW".U
M)D8#Q5][V[>BTJL5B5B*([%H)6U-N*X4A]OXPF2(FV[5'></-E85AJR<)&!8
MW+&-,)R:E#H[-9B+JE091)A1"=23KK3C>=0:4GEM4@C6E/":2,[+",!YP5BA
MK&>&(&)68RX:)I.6Q7%$M3:V75LJ*\G(?E(.PP&_
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MPZGPV>+SHW&?3FY$<W>XT:J4>D.49XJA*9>E,,6MWE,QE-(=47E<"5/MD?\
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MT.$\NF16V9$@BL)V097GG;#X+[BE+L]T$6$
M     ?"2E-I)(B(S,SLR93RF8#Z ^&1*(R,K2/(9'P6 /I$1$1$5A%D(B
M  <]W)?=S!_3ZS^MY8++H0(                YSOV^ZZL?Y],_648%AT8$
M                 % J_P!\^%/X>KWSNE +^                  .:;XO
MW!_C*C_E@5TL$                5;>7]W&,/H2I?-' $O!'[%X<^BX7S=
M#?
M                    #GNY+[N8/Z?6?UO+!9="!                '.=
M^WW75C_/IGZRC L.C @                 H%7^^?"G\/5[YW2@%_
M            '--\7[@_QE1_RP*Z6"                *MO+^[C&'T)4OF
MC@"7@C]B\.?1<+YN@!O@
M                                     !SW<E]W,']/K/ZWE@LNA @
M              #G._;[KJQ_GTS]91@6'1@0                 4"K_?/A
M3^'J]\[I0"_@                 #FF^+]P?XRH_P"6!72P0
M    !5MY?W<8P^A*E\T< 2\$?L7ASZ+A?-T -\
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MVQ]/]N_])P_&:OI1$TU3V6][I@^$_J@      <TWQ?N#_&5'_+ KI8(
M           JV\O[N,8?0E2^:. )>"/V+PY]%POFZ &^
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M/1BB*JBXI*=)E==SVOJ1G%6&LY'QII_L9SRKMEH\E?;W?<ZQV-^,*_!->_\
M>5/]+?\ ]10_7M#_ !T_"/P?YXXK_-7_ ,I_%KQW>8
M                            %UW1_>/A[])/_36/E?NO_5K^#[O[#_W]
M+X_RE^T1^7OW,      '--\7[@_QE1_RP*Z6"                *MO+^[C
M&'T)4OFC@"7@C]B\.?1<+YN@!O@
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MR3A(21J.\=IW/)2HRM++9D%IHF9B)V6DRL3:\XA*R(R)1$JP\AE:5N4<U>@
M   'X)KW_O*G^EO_ .JH?KVA_CI^$?@_SQQ7^:O_ )3^+7CN\P
M                                    +KNC^\C#WZ0?^FL?*_=?^K7\
M'W?V'_OZ7Q_E+]HC\O?N8      .:;XOW!_C*C_E@5TL$
M 5;>7]W&,/H2I?-' $O!'[%X<^BX7S= #?
M                                      X/&W%U=NA%$E.4N16&*#A^
MCPY:D.&;4FBU634'EH6:+R$+2\W<NY;R<O 0]DZ\6]_;-\.6!BG;E,43FJG3
MR31V6SB8NB1ZL9NJF3E8J-QQE4HB:*ZEHW+KOEKO&DE)L+R18UJ8W_[;C!/X
MMRK=WC:GL8G@T>/15O5*>_5(>(I'EU-Y$R2R\Y$=2[&=0VM+;:F4/VN)21-'
MF_),ACU*9LMM^"X9:Z'N:K[49MF9'I,TY;6*8LM4E2GUQD8B?:E1G$+5'23B
MFE-J0XFXV1YPU)[I'J=:/M[KDP,L/=%B6-4HC#C%&=@G4,/5A^O'G>4XAX>C
M0V5PXZ3:\IMU455Q>=1=0\Z1H,S\J3K19W]]YAE.P1N39H+-*B5N-39$)NA3
MZ/6VHJ%HUIZ;46IB34=U!K01)62KYVVJ[QF)7KVVV;_Y+%%CKT>.S$CM18Z;
MD=A"6FD93NH05U)6G:>0B'EET9     'Y]P+N>POCG#B<4UE^:BJ3IU4UHX[
MJ$MJ4Q4I+*575-JL.ZA-N4?=T/WOB-*B*(LF(W__ %_*\7_YC@]?5JU)Q4S5
MMG#,66[^SO[UC[..!/:JEZYK0CO[AXC=3X3YO+[0X/?7XQ_:=G' GM52]<UH
M0]P\1NI\)\SVAP>^OQC^T[..!/:JEZYK0A[AXC=3X3YGM#@]]?C']IV<<">U
M5+US6A#W#Q&ZGPGS/:'![Z_&/[3LXX$]JJ7KFM"'N'B-U/A/F>T.#WU^,?VG
M9QP)[54O7-:$/</$;J?"?,]H<'OK\8_M.SC@3VJI>N:T(>X>(W4^$^9[0X/?
M7XQ_:=G' GM52]<UH0]P\1NI\)\SVAP>^OQC^T[..!/:JEZYK0A[AXC=3X3Y
MGM#@]]?C']IV<<">U5+US6A#W#Q&ZGPGS/:'![Z_&/[3LXX$]JJ7KFM"'N'B
M-U/A/F>T.#WU^,?VG9QP)[54O7-:$/</$;J?"?,]H<'OK\8_M.SC@3VJI>N:
MT(>X>(W4^$^9[0X/?7XQ_:JF\G<OA#!^#IV(8#TYV5%=AH2V\\W<-,F8S'5;
M=;2=MUPS++P^ /</$[J?"?-?:'![Z_&/);.SC@3VJI>N9T(>X>(W4^$^:>T.
M#WU^,?VOG9QP)[54O7-:$/</$;J?"?,]H<'OK\8_M.SC@3VJI>N:T(>X>(W4
M^$^9[0X/?7XQ_:=G' GM52]<UH0]P\1NI\)\SVAP>^OQC^T[..!/:JEZYK0A
M[AXC=3X3YGM#@]]?C']IV<<">U5+US6A#W#Q&ZGPGS/:'![Z_&/[3LXX$]JJ
M7KFM"'N'B-U/A/F>T.#WU^,?VG9QP)[54O7-:$/</$;J?"?,]H<'OK\8_M.S
MC@3VJI>N:T(>X>(W4^$^9[0X/?7XQ_:=G' GM52]<UH0]P\1NI\)\SVAP>^O
MQC^T[..!/:JEZYK0A[AXC=3X3YGM#@]]?C']IV<<">U5+US6A#W#Q&ZGPGS/
M:'![Z_&/[3LXX$]JJ7KFM"'N'B-U/A/F>T.#WU^,?VG9QP)[54O7-:$/</$;
MJ?"?,]H<'OK\8_M5F=N3P=&Q_1,+(?GG"J-*J=0><-YO.$[ ?A--DD\U9=,I
M*[UI6Y$V69;;[AXC=3X3YGM#@\U?C']JS=G' GM52]<UH1/</$;J?"?,]H<'
MOK\8_M.SC@3VJI>N:T(>X>(W4^$^9[0X/?7XQ_:=G' GM52]<UH0]P\1NI\)
M\SVAP>^OQC^T[..!/:JEZYK0A[AXC=3X3YGM#@]]?C']IV<<">U5+US6A#W#
MQ&ZGPGS/:'![Z_&/[3LXX$]JJ7KFM"'N'B-U/A/F>T.#WU^,?VG9QP)[54O7
M-:$/</$;J?"?,]H<'OK\8_M;_".YW!^#:JFM4\I$FH-I4EAR6XE9-7RNJ-!(
M0@K3(S*T[1X^+_=]?B*,%5D1]G>^CP'_ )_A>#U/4HMFKNQ3V70Z /COZ,
M    '--\7[@_QE1_RP*Z6"                *MO+^[C&'T)4OFC@"7@C]B
M\.?1<+YN@!O@
M                             !SW<E]W,']/K/ZWE@LNA @
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MZ F>: =<$+8_%_0$SS0#K@A;'XOZ F>: =<$+8_%_0$SS0#K@A;'XOZ F>:
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M] 3/- .N"%L?B_H"9YH!UP0MC\7] 3/- .N"%L?B_H"9YH!UP0MC\7] 3/-
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MQ.903AI70I:5*M6E%B"-/E'Y5MA=PC/N .A @
M                                   .>[DONY@_I]9_6\L%ET($
M            <YW[?==6/\^F?K*,"PZ,"                 "@5?[Y\*?P
M]7OG=* 7\                  <TWQ?N#_&5'_+ KI8(
M JV\O[N,8?0E2^:. )>"/V+PY]%POFZ &^
M                                                    '/=R7W<P
M?T^L_K>6"RZ$"                .<[]ONNK'^?3/UE&!8=&!
M       !0*O]\^%/X>KWSNE +^                  .:;XOW!_C*C_ )8%
M=+!                %6WE_=QC#Z$J7S1P!+P1^Q>'/HN%\W0 WP
M            .._S!;P\=[OZ7AUS=]#BSZS5*@\T[$F-K<)V/$A/S%MHN*29
M+63-A&/5P^G37,XG.NJ8[%4Q5_,)6W<<;O:=@5B(]A&NN4!6(Y<I*EOMEBIQ
M6IL-W5IN.DRRZZJTC[G>,=*.'C#5-7;%MGW,S7MBQ"PC_,CB!B/O DX^AQ4-
M4:+4:QA$XJ%M%,BT^H/4M4=9J4HC<UA+""LX<X+7PT?EP]_;X6D:G;:\T'?M
MO)E;N9K%0B4U6^!5=JU!A0T(6W 9;HC*9$Z4\DW#4;<=%Y)V*\IPVT_A"U:%
M&/9^FR)\4BN;/M)N^?>I5:'%GX;<I,-^AX!A8_Q(N7%=?*:_+:6\4)E*749E
M!H:6K.7E':9%DX0C1HB=MNVK#"XYNM;C$.];>3#K>[>O49RDR\+;PYE,9IN$
M2CO*K!4^;";DRI:Y&<N_[<U'>NM7$IN&KA,8ITJ)BJ)MMIMV]RS5.S[7Z$'B
M=0                               %#IF];#\VO8KH\M#E.B86;5)759
M)DF-+C1C4W,=9L\J[%>0IETS+WW .TZ4Q$3O9Q)&*-ZN"L(+8:JTY:W7IT2F
M+:B-+DN,O3VEOL&ZELC42%(0I5I$8E.E55V$U1#[0]YN%ZRBGD4UE,FL/2D4
MN.P;DA3K$64J(3JR2V1LD:TW5$Z2;J_(M-1!5I51]Q%4(R=].ZQ1.&G%$,TM
MV&M1&LTW+ZFE.$=VPVT+2:7'"\AL\BS(7T:]R8X9\5X_5A_$U#PE I9U*L5M
MI^4RE<EF"UF(BVD.$TM\R)U[XTE$RG+=)2C,B(2C3MB9M[%FJR;$R/O'P-*K
M;^'6:[%56(RY#3\<U&DD.PDWWVS6HB1?;1Y:T7KQ)\JR[E$].JRVPQ0PHWI8
M 72GZRFN,ZA'=8CK,T.DZ;LLB-A+;)HSCF=([S1H09+*TTVD1B^E5;988H06
M=\V[UR77XSU5U1C#3$274ZA*:6S#)BH)0IE:'E%=5;G$)LX;3%]&O9L[3%#>
M1L<X3ELMOL51HT.OQ8:"62VUZS4$)<CM&E:24E3B5I-)*+NC$T5;EMAI3WT;
MK2)Y7VGB76+3<45\TDA#BFG%D=VPT-K2:75EY+9^_-(WZ->Y,<+T1DHB4D[2
M/*1EP&0XM/H  _(K&\#%^%#DX?H52.-28<R:<9HV65*(I$IU]1J4I"C,S4X?
M=]P?WG#?M'#^G3BC%-FV;9?E_%_OW%SK58:L--MD19'=]W:S=<6\7GD_41]&
M/1TGA<E\^;R]=XW/=3Y'7%O%YY/U$?1ATGA<E\^9UWC<]U/D=<6\7GD_41]&
M'2>%R7SYG7>-SW4^1UQ;Q>>3]1'T8=)X7)?/F==XW/=3Y'7%O%YY/U$?1ATG
MA<E\^9UWC<]U/D=<6\7GD_41]&'2>%R7SYG7>-SW4^1UQ;Q>>3]1'T8=)X7)
M?/F==XW/=3Y'7%O%YY/U$?1ATGA<E\^9UWC<]U/D=<6\7GD_41]&'2>%R7SY
MG7>-SW4^1UQ;Q>>3]1'T8=)X7)?/F==XW/=3Y'7%O%YY/U$?1ATGA<E\^9UW
MC<]U/D=<6\7GD_41]&'2>%R7SYG7>-SW4^1UQ;Q>>3]1'T8=)X7)?/F==XW/
M=3Y-?6MY&,\0TYRDU>I:S >4TMQE3+))4IAQ+J+;J"/(M"3X>YWA>D\+DOGS
M.N\;]2ZGR;#KBWB\\GZB/HQ.D\+DOGS.N\;GNI\CKBWB\\GZB/HPZ3PN2^?,
MZ[QN>ZGR.N+>+SR?J(^C#I/"Y+Y\SKO&Y[J?(ZXMXO/)^HCZ,.D\+DOGS.N\
M;GNI\CKBWB\\GZB/HPZ3PN2^?,Z[QN>ZGR.N+>+SR?J(^C#I/"Y+Y\SKO&Y[
MJ?(ZXMXO/)^HCZ,.D\+DOGS.N\;GNI\CKBWB\\GZB/HPZ3PN2^?,Z[QN>ZGR
M"WQ;Q2,CY9,[,MF8CZ,.D\+DOGS.N\;GNI\GZ(W;XFF8MPE#K%00E$U2G&7S
M;*Q"E-*--XB[EI<)=\?QG[APU.AK313V/T3]JXNKBN'IU*NW;$_<M@^<^L
M  H%7^^?"G\/5[YW2@%_                  '--\7[@_QE1_RP*Z6"
M            *MO+^[C&'T)4OFC@"7@C]B\.?1<+YN@!O@
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MQ_ ?O7_9GX0_5/\ SO\ TX^,_BZ./B/Z,   !0*O]\^%/X>KWSNE +^
M             .:;XOW!_C*C_E@5TL$                5;>7]W&,/H2I?
M-' $O!'[%X<^BX7S= #?                    KV+L3GAF-3TQHISZO6)[
M%+I<(E&V3C[YFI:UK)*[J&F4./+.[[U!]VP!2XF_:@.2IAS*;*C45F)6*C$J
MJ5QY"'XN'Y&K2%FTTX;C5]9EF,XDLY;9D5D!;%EK>,JCAW=ZO&M7I&:J$>,Q
M+FT8GR-3.>6@EMFZ:2(U-I7E\FPU%D!'K>%O"I6[BEP:M5H[\IB;/8IY(BDE
M3C9/7E+>42E)\AI"5+79EL(!K,2[W:!AK$<W#CD65,>I5(FUVL2HR4&Q%8@L
MI>S2S4HK77$J2:4EP$I)G82B!;&KG;[8]#@U=>)L,U*EUJF4QBMQZ1>CR79L
M.4^F*DF5LN*3G4O+2VMM=AD9I,KQ&!8W%1WKT"%-P;3HT>1/FXS..Y#:CD@S
MC1)39K3(D&:B)*,ETK+349'9;=,$86M[-,G.XX8ID!]Y6#(BY:)#II:CU'-)
MD$Z495JE76WHSD=:S39?([+; 5=J/4FJS28%782:&:A&9EMH5[XDOH)PB/W2
M(P1-                             4W>IB.K83P)5*[0U-(JK"HC4=R0
MV;S2#E2V8YJ-!*1>L2X9D5XLHZZ5,551$LU39"J'CG%% Q26#,2S69LAJI4<
MHM4IT9#2I,.M(GD3$EAUU1-+;<@K^,:4=Y)HL21WATP4S3BC[;K/-FV8FQ*I
MN^=%:@4E=(H+TNNUV1)8IM&3*CI=0B"PE^0J8M1D49QJ^EM;*RODLR+*7E"3
MHV3-L[(7&PM[]Z2_#=K,>ASW,.PJ*S7ZI434PE4=,E<EAJ*3)N7W)!OQ7&C)
M/D$=AWK!?0GLMVVV)C:_KBJ]"JV($8MIIPE\H4JDT2C.O1TI:?ET]R:\IR8@
MS0;=UI:KQVF1IND64AKT8F(L^TQ6=JR86WKMXQJ](IM&P_/U:H4IJMS9THVH
MZ(;,AZ3'0VI"U7UK-R,HBN)NFDR5;8.=6EAB9F>^Q8JM5NL;SZQ"HN+ZHQ/B
MPYSN)BPAA)-2)"(,=]E+;2WGUE=4:;Y2'U6J]ZDDE[O2-*)F(^RV4FKM1I>]
MFO5&CX+QC'EMT/ -4AF[7\0(A'4V8U39?0RN-()+B<Q&-27D:SY22417C27O
MD:41,QVRF+LGN2&<?X[CRYV(I,J!)PS%QC]DGJ(<93,E,61.:@,R&9).JONH
M6ZA:T*;NJ1>LNF1&'IT]G?9:N*;UXW:UZH5RBU%BK2#EU.B5>I463,-"6L^4
M&2M+3EU!$1&;1MWK/PK1QU*8B=G?$-4S:N0Y-   _#]:,E5FI*2=Y&MR"2M.
M5*KKJDF:3[I6D9?_ *C]1X74IKTJ:J9MBR'XIQFG5IZ]=-463%4_Q\$*PQZ7
MD+# +# +# +# +# +# +# +# +# +# +# +# ?#,DE:>0@29L?0"PP4L, L,
M L, L, L, L, L,!^K]S4"93\ P&YS*F'77'GD-N$:59MQ9FDS(\I6EE+W!^
M>_N]=-?$SAFWL?J_[#I54<'3%466VS>OP^.^^    H%7^^?"G\/5[YW2@%_
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MYN@!O@
M                       !SW<E]W,']/K/ZWE@LNA @
M#G._;[KJQ_GTS]91@6'1@0                 4"K_?/A3^'J]\[I0"_@
M               #FF^+]P?XRH_Y8%=+!                %6WE_=QC#Z$
MJ7S1P!+P1^Q>'/HN%\W0 WP                  _,E2WKX\CU&9':JMUII
M]U"$YA@[$I69$65'>'W*>&TYB-C^3KX_7BJ8Q=^Z$;K=W@<[?(,:,7E=/<QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=
MW@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=
MW@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=
MW@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=
MW@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=
MW@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU
M#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C
M1ARNGN.H:^:Z&OHN\+%^'J>FETFH9B$AQ]]+1,M*(ERGEON':M)GE6XI7#DM
MR9 Y73W'4-?-=#8=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70
M=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNG
MN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?
M(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70
M=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNG
MN.H:^:Z&NKF\'%N(Z:[2*O/*13WEM..,FRTDC4PZEY%II21Y%H2?#_\  <KI
M[CJ&OFNAL>MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!S
MM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-
M=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*
MZ>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!S
MM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-
M=!UN[P.=OD&-&'*Z>XZAKYKH07=XV,7JQ%KKE1MJD*/(AQG\RT5UB8MEQU-A
M(NG>5';.TRM\G)W0Y73W'4-?-="=UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@Q
MHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN
M[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZ
MAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@Q
MHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN
M[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=#75;>#BRN:CRG.)_DV
M6U48=K+)9N5'MS:RNH+*5X^'('*Z>XZAKYKH;'K=W@<[?(,:,.5T]QU#7S70
M=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNG
MN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?
M(,:,.5T]QU#7S70=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70
M=;N\#G;Y!C1ARNGN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70=;N\#G;Y!C1ARNG
MN.H:^:Z#K=W@<[?(,:,.5T]QU#7S70B5/>9C6L4V92:A4L[ GL.1936993?9
M?0:%IM2@C*U)F60[0Y73W'4-?-=#)#WI8Y@1(\&+4R;BQFT,L-DPQ8EMM))2
M65'<(@Y73W'4-?-=#/UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?
M-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'
M*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!
MSM\@QHPY73W'4-?-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?
M-=!UN[P.=OD&-&'*Z>XZAKYKH.MW>!SM\@QHPY73W'4-?-=!UN[P.=OD&-&'
M*Z>XZAKYKH28F]?'CK$YQ=5M4RP2V_B&,BC?:1;[SO*,2>&T]FQNGC]>8G\W
M=NC?"F5G_P!Q4/TE[_44/31^F'@U/US\4)*5K.Q"%+5WD)-1^ B,:<PTJ2=B
MTFE1<*5$:3\!Y0'IMMQYQ#+*%./.*)#;:"-2E*4=A$1%E,S"9L6(F9LA\4E2
M%*0M)I6@S2M*BL,E$=AD9'P&1@@E#B[<VVM=G#<2I=G]-TC LEY([>
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MSP"
M
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MD
M
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M
M
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MZ=QTF,UQV?8G/SG%DZ0.>G<=)C-<=GV)S\YQ9.D#GIW'28S7'9]B<_.<63I
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M9V-PL5EJ2V5<</6&R:,]63DL<0Y;^,_N6#,\;.YJ/VJ(M_-V_8["/G/N
M                                                       Y[N2^
M[F#^GUG];RP670@0               !SG?M]UU8_P ^F?K*,"PZ,"
M           "@5?[Y\*?P]7OG=* 7\                  <TWQ?N#_ !E1
M_P L"NE@@               "K;R_NXQA]"5+YHX EX(_8O#GT7"^;H ;X
M
M                <]W)?=S!_3ZS^MY8++H0(                YSOV^ZZ
ML?Y],_648%AT8$                 % J_WSX4_AZO?.Z4 OX
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MS1-DNE-5JW#DT
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M?\L"NE@@               "K;R_NXQA]"5+YHX EX(_8O#GT7"^;H ;X
M                %$QWNP@8[K=$K<NH/PWJ)"K5/::82VI+B*]$3$<4HUD9
MD;9)O(L[O".VGJS1$QOLN8FFU"B[H*=$=W:O,U62E>[2!)IU.,D-_P"Y3*IZ
M:>;CMI'8I*4WRNY+>'(+.M/YMGZC#V?8][KMU+6[:1B&H*JRJG4<2/L2)I-1
M(U,A(5&;-LEMQ(B4MI=<O&I]POQBK#L*P-75QV;.PIIL=%'!L
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MKB7@<6@    !^(*W_P"ZJ/Z4_P#ZBA^J:/\ CI^$/Q#B/\M7QG\4 =GG
M                         'ZGW&_=]$_2)'^H8_@/WK_LS\(?JG_G?^G'
MQG\71Q\1_1@   *!5_OGPI_#U>^=TH!?P                 !S3?%^X/\
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MDI<9@2)*KAH6M/DFVVN\2C*[:1V'P!T<$
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M'2*<JIU&)'4:UR'*S77E*E2'59$W6V3S+"2+(E:K>!("^@@
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M"                *MO+^[C&'T)4OFC@"7@C]B\.?1<+YN@!O@
M
M        !SW<E]W,']/K/ZWE@LNA @               #G._;[KJQ_GTS]9
M1@6'1@0                 4"K_ 'SX4_AZO?.Z4 OX
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MU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7
M*)ODK.]%_=U5&JIA*EQ(9O4^^^U6EOK(RJ$<TE<."W;:JPC\K)P^X!"^'7]\
M%IV8*I!EW#Y?<^KP'SE_?!L32.GW/JX Y?WP;$TCI]SZN .7]\&Q-(Z?<^K@
M#E_?!L32.GW/JX Y?WP;$TCI]SZN .7]\&Q-(Z?<^K@#E_?!L32.GW/JX Y?
MWP;$TCI]SZN .7]\&Q-(Z?<^K@#E_?!L32.GW/JX Y?WP;$TCI]SZN .7]\&
MQ-(Z?<^K@#E_?!L32.GW/JX!3*G6=Z2MZV&GG,(TI-030JVEB,5;6:%M*E4S
M.*->HD:329((DW#O7C.TKH"Y\O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R_O@V)I
M'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^
MY]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5
MP!R_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P"@[T:SO.>^Q7*6$Z
M9&N8KI2XN:K*WLX^6=NH5;"1=(_[66SO& OW+^^#8FD=/N?5P!R_O@V)I'3[
MGU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7
M '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R
M_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P"NX_KF]=S >*6YN#Z4Q
M#72*@E]Y%<6XM#9Q7"4HD' 3>,BRV7BM[X"5A*N;V6\*4)$7!M)=C)IT,FG5
M5U:%*03"+#-.H*LM+N6F W'+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T
M^Y]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?
M5P!R_O@V)I'3[GU< <O[X-B:1T^Y]7 '+^^#8FD=/N?5P!R_O@V)I'3[GU<
M<O[X-B:1T^Y]7 '+^^#8FD=/N?5P#VW7=[9I=-S!E)0I*+62*NN*O.7TE=,^
M3RL*Z:E6Y<I6=VTB+Z
M                 #GNY+[N8/Z?6?UO+!9="!                '.=^WW
M75C_ #Z9^LHP+#HP(                 *!5_OGPI_#U>^=TH!?P
M          !S3?%^X/\ &5'_ "P*Z6"                *MO+^[C&'T)4O
MFC@"7@C]B\.?1<+YN@!O@
M                                      !SW<E]W,']/K/ZWE@LNA @
M               #G._;[KJQ_GTS]91@6'1@0                 4"K_?/
MA3^'J]\[I0"_@                 #FF^+]P?XRH_Y8%=+!
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MCNF?<L[HWJ:<T39*4U1*X#DT
M        YWN4<0C=S!OJ)-L^LV6F1?\ ^O+%B+29B'0,^QZ5'PB%PRSBC>9]
MCTJ/A$&&3%&\S['I4?"(,,F*-[VE25E:DR47?([2&;%B;7T%          !S
MG?M]UU8_SZ9^LHP+#HP(                 *!5_OGPI_#U>^=TH!?P
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MM,VS4W8I*K."\7?[P_G_ -\TZ9T,5FV)A_5_^:UJXXG!$_EF)V/TR/X5^F
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MHP+#HP(                 *!5_OGPI_#U>^=TH!?P
M!S3?%^X/\94?\L"NE@@               "K;R_NXQA]"5+YHX EX(_8O#GT
M7"^;H ;X
M                          <]W)?=S!_3ZS^MY8++H0(
M   YSOV^ZZL?Y],_648%AT8$                 % J_P!\^%/X>KWSNE +
M^                  .:;XOW!_C*C_E@5TL$                5;>7]W&
M,/H2I?-' $O!'[%X<^BX7S= #?
M                                            #GNY+[N8/Z?6?UO+
M!9="!                '.=^WW75C_/IGZRC L.C @
MH%7^^?"G\/5[YW2@%_                  '--\7[@_QE1_RP*Z6"
M          *MO+^[C&'T)4OFC@"7@C]B\.?1<+YN@!O@
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MXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC
M.I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=
M-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0
M.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXF
MC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I
M[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L+0.BXFC .I[=-L
M+0.BXFC #W/;IC_<6@=%PR_) '4]NFV%H'1<31@'4]NFV%H'1<31@'4]NFV%
MH'1<31@'4]NFV%H'1<31@'4]NFV%H'1<31@'4]NFV%H'1<31@'4]NFV%H'1<
M31@'4]NFV%H'1<31@'4]NFV%H'1<31@'4]NFV%H'1<31@'4]NFV%H'1<31@'
M4]NFV%H'1<31@'4]NFV%H'1<31@!;GMTQ?N+0/ZZ7#/\D =3VZ;86@=%Q-&
M=3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ
M;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@
M=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-
M& =3VZ;86@=%P]$ =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3
MVZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;8
M6@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%
MQ-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%P]$ =3VZ;86@=%Q-&
M=3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ
M;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@
M=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%P]
M$ =3VZ;86@=%Q-$ =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3
MVZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;8
M6@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%Q-& =3VZ;86@=%
MQ-& =3VZ;86@=%Q-& ]HW2;K&DNH;P30D(>23;R4TR(1+02DK)*B)O*5Y*5?
MTD0"Y
M
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M&)BR6HFUM1E0
M
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MFRY"XK;K7Q[QK2YGEI6:G$E8E2DW;$'9Y)6D0Q:MC8B*
M
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M$\ZA#QO(-YE#QOJ,FS:2VC.)2I)N7N$^\1L&PM78<V@
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MM:$DA*UM)63:E$DB22E),[!,4V%C:B*
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M:<TA49.<D3F;\<K75J<(DF1YPKI*([#20UAB)2V;'41Q;
M
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MH3B38M8PT
<                                  /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
